

CITATION REPORT

List of articles citing

Human memory and the cholinergic system. A relationship to aging?

DOI: 10.1001/archneur.1974.00490320001001
Archives of Neurology, 1974, 30, 113-21.

Source: <https://exaly.com/paper-pdf/11702447/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1356	Current publications in gerontology and geriatrics. 1974 , 29, 591-614		
1355	Brain-decarboxylase activities as indices of pathological change in senile dementia. 1974 , 1, 1247-9		62
1354	Deanol and methylphenidate in minimal brain dysfunction. 1975 , 17, 534-40		23
1353	Effects of diazepam and scopolamine on storage, retrieval and organizational processes in memory. 1975 , 44, 257-62		248
1352	Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. 1975 , 32, 375-80		146
1351	Neurochemistry of Cholinergic Terminals. 1976 , 99-228		33
1350	Secondary metabolic encephalopathy. Diagnosis and treatment. 1976 , 59, 122-8		
1349	Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. 1976 , 5, 39-46		289
1348	Physostigmine: effects on cognition and affect in normal subjects. 1976 , 51, 23-7		129
1347	Behavioral effects of organophosphate in man. 1976 , 9, 391-403		72
1346	Pheniramine aminosalicylate overdose. Reversal of delirium and choreiform movements with tacrine treatment. <i>Archives of Neurology</i> , 1977 , 34, 313		11
1345	Memory enhancement after physostigmine treatment in the amnesic syndrome. <i>Archives of Neurology</i> , 1977 , 34, 215-9		88
1344	Senile dementia: treatment with deanol. 1977 , 25, 241-4		27
1343	Neocortical cholinergic neurons in elderly people. 1977 , 1, 668-71		391
1342	The biochemistry of brain development and mental retardation. 1977 , 131, 565-74		3
1341	Transmitters in Dementia. 1977 , 131, 318-319		10
1340	Selective vulnerability of neurones in organic dementia. 1977 , 266, 558-9		106

- 1339 Studies on human memory: the interactions of diazepam, scopolamine, and physostigmine. **1977**, 52, 1-6 199
- 1338 Scopolamine induced learning failures in man. **1977**, 52, 283-9 145
- 1337 Limbic lobe involvement in presenile dementia. **1978**, 226, 79-93 61
- 1336 Short-term memory in the rhesus monkey: effects of dopamine blockade via acute haloperidol administration. **1978**, 9, 353-7 49
- 1335 Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. **1978**, 9, 833-6 161
- 1334 Possible biochemical basis of memory disorder in Alzheimer disease. **1978**, 3, 471-3 79
- 1333 Physostigmine: improvement of long-term memory processes in normal humans. **1978**, 201, 272-4 412
- 1332 Cholinergic underactivity in human memory disorders. **1978**, 23, 1729-33 89
- 1331 A clinical method of estimating risk of drug induced delirium. **1978**, 22, 1511-6 34
- 1330 Choline: Selective enhancement of serial learning and encoding of low imagery words in man. **1978**, 22, 1555-60 63
- 1329 Anticholinergic Delirium: Etiology, Presentation, Diagnosis and Management. **1978**, 10, 237-241 11
- 1328 Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. **1978**, 2, 1457-9 1578
- 1327 Cognitive functions in manic-depressives: effects of lithium and physostigmine. **1978**, 133, 424-8 32
- 1326 Human serial learning: enhancement with arecholine and choline impairment with scopolamine. **1978**, 201, 274-6 469
- 1325 Biochemical aspects of the aging brain. **1978**, Suppl, 4-11 8
- 1324 Functional implications of changes in the senescent brain: a review. **1978**, 5, 417-24 17
- 1323 Physostigmine and recent memory: effects in young and aged nonhuman primates. **1979**, 206, 1087-9 188
- 1322 Pure memory loss with hippocampal lesions: a pneumoencephalographic study. *Archives of Neurology*, **1979**, 36, 54-6 57

1321	Effects of physostigmine and lecithin on memory in Alzheimer disease. 1979 , 6, 219-21	186
1320	EEG effects of physostigmine and choline chloride in humans. 1979 , 62, 225-33	10
1319	The effects of deanol on cognitive performance and electrophysiology in elderly humans. 1979 , 66, 99-104	9
1318	Effect of scopolamine on maze learning performance in humans. 1979 , 35, 1069-70	20
1317	Choline acetyltransferase and acetylcholinesterase abnormalities in senile dementia: importance of biochemical measurements in human post-mortem brain specimens. 1980 , 1, 75-83	2
1316	The effects of blood sludging upon short-term memory in rats and rhesus monkeys: an evaluation of its role in age-related cognitive declines. 1979 , 22, 715-22	2
1315	Memory. 1979 , 1, 666-7	1
1314	The role of the cholinergic nervous system in memory consolidation. 1979 , 13, 9-11	21
1313	Psychopharmacological prospectives in the treatment of dementia. 1979 , 3, 75-80	2
1312	DITHRANOL FOR PSORIASIS. 1979 , 313, 666	
1311	Relevance of cerebrovascular changes to mental function. 1979 , 9, 173-83	11
1310	Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. 1979 , 171, 319-27	617
1309	Four stimulants of the central nervous system: effects on short-term memory in young versus aged monkeys. 1979 , 27, 289-97	30
1308	Evidence for a cholinergic projection to neocortex from neurons in basal forebrain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1979 , 76, 5392-6	11.5 323
1307	Choline, acetylcholine and dementia. 1980 , 10, 1-3	17
1306	Age-related changes in passive avoidance retention: modulation with dietary choline. 1980 , 209, 301-3	264
1305	Cardiovascular effects produced by choline injected into the lateral cerebral ventricle of the unanesthetized rat. 1980 , 26, 1029-36	9
1304	Some biological aspects of the aging brain. 1980 , 14, 191-201	17

1303	Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. 1980 , 1, 333-6	162
1302	Biochemistry of dementia and normal ageing. 1980 , 3, 55-57	19
1301	Some effects of atropine on short-term memory. <i>British Journal of Clinical Pharmacology</i> , 1980 , 10, 627-8.8	15
1300	Memory deficits in aged cebus monkeys and facilitation with central cholinomimetics. 1980 , 1, 145-52	164
1299	Quantitative evidence for selective dendritic growth in normal human aging but not in senile dementia. 1981 , 214, 23-41	231
1298	Partial reversal of anticholinergic amnesia by choline chloride. 1981 , 29, 1317-23	23
1297	Age-related differences in behavior across the life span of the C57BL/6J mouse. 1981 , 7, 427-51	176
1296	Hidden memory: a rapid method for the study of amnesia using perceptual learning. 1981 , 17, 273-8	17
1295	Age-related alterations in neurotransmitter receptors: an electrophysiological and biochemical analysis. 1981 , 2, 3-8	169
1294	Age and neurochemical correlates of radial maze performance in rats. 1981 , 2, 41-7	196
1293	Presynaptic cholinergic mechanisms in brain of aged rats with memory impairments. 1981 , 2, 99-104	130
1292	Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. 1981 , 2, 105-11	134
1291	Memory failures in progressive idiopathic dementia.. 1981 , 90, 187-196	168
1290	Chapter 6. Memory and Learning. 1981 , 51-60	4
1289	Choline stimulates nicotinic receptors on adrenal medullary chromaffin cells to induce catecholamine secretion. 1981 , 214, 466-8	27
1288	Qualitative analysis of scopolamine-induced amnesia. 1981 , 74, 74-80	244
1287	Tricyclic antidepressants and peripheral anticholinergic activity. 1981 , 74, 325-8	21
1286	Decreased verbal memory associated with anticholinergic treatment in Parkinson's disease patients. 1981 , 14, 61-6	40

1285	Clinical response to choline plus piracetam in senile dementia: relation to red-cell choline level. 1981 , 304, 1490-1	51
1284	Brain acetylcholine synthesis declines with senescence. 1981 , 213, 674-6	222
1283	Effects of anticholinergic drugs on memory in Parkinson's disease. <i>Archives of Neurology</i> , 1982 , 39, 666-7	64
1282	Aphasia after right thalamic hemorrhage. <i>Archives of Neurology</i> , 1982 , 39, 667-9	25
1281	Selective effects of cholinergic treatment on verbal memory in posttraumatic amnesia. 1982 , 4, 219-34	31
1280	Dementia. 1982 , 66, 1143-60	5
1279	The EEG in chronic psychotropic drug intoxications. 1982 , 13, 206-15	3
1278	The interaction of chronic alcohol consumption and aging on brain structure and function. 1982 , 6, 13-21	38
1277	Cholinergic and Serotonergic Systems in the Brain and Spinal Cord: Anatomic Organization, Role in Intercellular Communication Processes, and Interactive Mechanisms. 1982 , 55, 3-40	16
1276	A processing resource account of age differences in recall. 1982 , 36, 325-344	229
1275	Cholinergic projections from the basal forebrain to frontal, parietal, temporal, occipital, and cingulate cortices: a combined fluorescent tracer and acetylcholinesterase analysis. 1982 , 8, 727-49	688
1274	Rapid forgetting in aged rats. 1982 , 36, 49-60	120
1273	Phosphatidyl choline and avoidance performance in 17 month-old SEC/1ReJ mice. 1982 , 30, 1065-71	25
1272	The cholinergic hypothesis of geriatric memory dysfunction. 1982 , 217, 408-14	4821
1271	Decreases in the release of acetylcholine in vitro with low oxygen. 1982 , 31, 111-5	54
1270	Alzheimer's disease and Down's syndrome. 1982 , 396, 145-64	81
1269	Memory and postsynaptic cholinergic receptors in aging mice. 1982 , 17, 313-22	45
1268	Lecithin treatment of cognitively impaired Parkinson's patients. 1982 , 12, 87-90	6

1267	Biochemistry of Alzheimer's dementia. 1982 , 39, 9-15	93
1266	Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. 1982 , 38, 1490-2	127
1265	Presidential address, 1982. The pharmacology of human information processing. 1983 , 20, 359-70	114
1264	Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat. 1983 , 18, 973-81	333
1263	Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). 1983 , 10, 1185-201	2009
1262	Loss of cholinergic neurons in the rat neocortex produces deficits in passive avoidance learning. 1983 , 19, 309-12	120
1261	Effects of cholinergic drugs on delayed match-to-sample performance of rhesus monkeys. 1983 , 19, 963-7	91
1260	Memory and the septo-hippocampal cholinergic system in the rat. 1983 , 81, 315-20	147
1259	Oral physostigmine and lecithin improve memory in Alzheimer disease. 1983 , 13, 491-6	270
1258	Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. 1983 , 214, 170-97	1661
1257	Effects of d-amphetamine, Org 2766, scopolamine, and physostigmine on repeated acquisition of four-response chains in rat. 1983 , 3, 37-48	17
1256	Measurement of cholinergic drug effects on memory in Alzheimer's disease. 1983 , 4, 139-45	65
1255	Reduced resistance to progressive extinction in senescent rats: a neuroanatomical and behavioral study. 1983 , 4, 203-15	15
1254	Amelioration of age-related neurochemical and behavioral deficits by 3,4-diaminopyridine. 1983 , 4, 25-30	55
1253	Amnesia-producing drugs affect hippocampal frequency potentiation. 1983 , 10, 697-706	9
1252	Alzheimer's disease: a disorder of cortical cholinergic innervation. 1983 , 219, 1184-90	2801
1251	The failing brain. 1983 , 36, 3-13	12
1250	Aged rats: recovery of motor impairments by intrastriatal nigral grafts. 1983 , 221, 966-9	144

1249	Improvement of 8-arm maze performance in aged Fischer 344 rats with 3,4-diaminopyridine. 1983 , 9, 211-4	60
1248	THE CHOLINERGIC SYNAPSE AND THE SITE OF MEMORY. 1983 , 367-386	21
1247	Neurotransmitter deficits in Alzheimer's disease: criteria for significance. 1983 , 31, 310-6	6
1246	Use of anticholinergics in the nursing home: an empirical study and review. 1983 , 17, 470-3	15
1245	The withdrawal of benztropine mesylate in chronic schizophrenic patients. 1983 , 143, 584-90	54
1244	Toward an effective treatment of Alzheimer's disease. 1983 , 98, 251-3	11
1243	EFFECT OF 4-(o-BENZYLPHENOXY)-N-METHYLBUTYLAMINE HYDROCHLORIDE (MCI-2016) ON THE SCOPOLAMINE-INDUCED DEFICIT OF SPONTANEOUS ALTERNATION BEHAVIOR IN RATS. 1983 , 33, 775-784	3
1242	Delirium and Dementia (Organic Brain Syndromes). 1984 , 141-167	
1241	Effects of Idebenone (CV-2619) on the Concentrations of Acetylcholine and Choline in Various Brain Regions of Rats with Cerebral Ischemia. 1984 , 36, 357-363	3
1240	Accidental poisoning with deadly nightshade berries: a case report. 1984 , 3, 513-6	23
1239	Classification of dementia patients by a WAIS profile related to central cholinergic deficiencies. 1984 , 6, 393-400	47
1238	Therapieversuche bei Demenz. 1984 , 11, 118-120	
1237	Reduction in muscarinic receptor binding in limbic areas of Alzheimer brain. 1984 , 47, 651-2	44
1236	The effects of intravenous diazepam and hyoscine upon human memory. 1984 , 36, 133-44	73
1235	Neural inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey. 1984 , 107 (Pt 1), 253-74	263
1234	A possible mechanism for diisopropylfluorophosphate-induced memory loss in rats. 1984 , 21, 43-6	33
1233	Varieties of perseveration. 1984 , 22, 715-32	308
1232	Neuroleptic neurotoxicity; electro-clinical aspects. 1984 , 69, 137-46	7

1231	Cholinergic hypothesis of human memory: Review of basic and clinical studies. 1984 , 4, 481-488	14
1230	Nootropic drugs: Animal models for studying effects on cognition. 1984 , 4, 567-576	108
1229	Cognitive analysis of neuropharmacological treatments. 1984 , 4, 577-589	1
1228	Alzheimer's disease. A metabolic systems degeneration?. 1984 , 2, 103-14	93
1227	Spatial learning and motor deficits in aged rats. 1984 , 5, 43-8	433
1226	Choline acetyltransferase: purification and immunohistochemical localization. 1984 , 34, 2319-38	72
1225	Intrusions and perseverations. 1984 , 23, 148-58	86
1224	Impairment in T-maze reinforced alternation performance following nucleus basalis magnocellularis lesions in rats. 1984 , 13, 63-70	109
1223	Some psychophysiological and pharmacological correlates of a developmental, cognitive and motivational theory. 1984 , 425, 58-151	31
1222	Dementia--Alzheimer type. 1984 , 59, 35-42	16
1221	Behavioural plasticity and the cholinergic system. 1984 , 8, 133-51	29
1220	Effects of aging on rat cortical presynaptic cholinergic processes. 1984 , 5, 315-7	76
1219	Microinjection of procaine or GABA into the nucleus basalis magnocellularis affects cue-elicited unit responses in the rat frontal cortex. 1984 , 85, 283-96	40
1218	Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. 1984 , 20, 307-11	46
1217	Test profile of cholinergic dysfunction and of Alzheimer-type dementia. 1984 , 6, 380-92	86
1216	Alzheimer's disease: clinical features, pathogenesis, and treatment. 1984 , 18, 684-91	12
1215	Pharmacotherapy of memory loss in the geriatric patient. 1984 , 18, 784-91	5
1214	The relationship between dietary intake of choline, choline serum levels, and cognitive function in healthy elderly persons. 1984 , 32, 208-12	16

1213	Effects of bifemelane hydrochloride (MCI-2016) on experimental amnesia (passive avoidance failure) in rodents. 1985 , 39, 153-61	16
1212	Multiple memory deficits in Alzheimer-type dementia: implications for pharmacotherapy. 1985 , 15, 527-41	51
1211	Scopolamine challenges in Alzheimer's disease. 1985 , 87, 247-9	58
1210	Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. 1985 , 86, 245-52	142
1209	The effects of scopolamine upon verbal memory: evidence for an attentional hypothesis. 1985 , 58, 205-17	69
1208	Rates of forgetting in Alzheimer-type dementia and Korsakoff's syndrome. 1985 , 23, 623-38	253
1207	Drugs that facilitate cognitive processes: Characterizing the response. 1985 , 5, 25-38	6
1206	Neuropathological processes in Alzheimer's disease. 1985 , 5, 59-68	5
1205	Development of cholinergic drugs for the treatment of Alzheimer's disease. 1985 , 5, 77-96	41
1204	Classical conditioning of the eyelid response in rabbits as a model system for the study of brain mechanisms of learning and memory in aging. 1985 , 11, 109-22	46
1203	Memory performance in individuals with primary degenerative dementia: its similarity to diazepam-induced impairments. 1985 , 11, 151-5	26
1202	A critical review of the role of the cholinergic system in human memory and cognition. 1985 , 444, 212-7	47
1201	Catecholamine system involvement in age-related memory dysfunction. 1985 , 444, 242-54	88
1200	The functional organization of the basal forebrain cholinergic system in primates and the role of this system in Alzheimer's disease. 1985 , 444, 287-95	24
1199	The cholinergic hypothesis: a historical overview, current perspective, and future directions. 1985 , 444, 332-58	291
1198	Models of memory dysfunctions. 1985 , 444, 359-69	68
1197	Interaction of choline and scopolamine in human memory. 1985 , 37, 193-7	16
1196	Is cholinergic activity of the caudate nucleus involved in memory?. 1985 , 37, 2135-42	44

1195	Further characterizations of the nature of the behavioral and neurochemical effects of lesions to the nucleus basalis of Meynert in the rat. 1985 , 6, 125-30	78
1194	Therapeutic applications of neural transplant technology. 1985 , 6, 169-172	1
1193	Lesioning of the rat basal forebrain leads to memory impairments in passive and active avoidance tasks. 1985 , 328, 97-104	139
1192	Basal forebrain innervation of rodent neocortex: studies using acetylcholinesterase histochemistry, Golgi and lesion strategies. 1985 , 337, 19-39	66
1191	Conformational changes in muscarinic receptors may produce diminished cholinergic neurotransmission and memory deficits in aged rats. 1985 , 6, 317-23	78
1190	Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. 1985 , 48, 413-21	424
1189	Alzheimer's disease. 1985 , 31, 1-69	13
1188	Pharmacologic management of obstructive lung disease. Current perspectives. 1986 , 81, 8-15	5
1187	Multiple muscarinic receptors in the CNS. Significance and prospects for future research. 1986 , 35, 3895-901	23
1186	Oxiracetam prevents electroshock-induced decrease in brain acetylcholine and amnesia. 1986 , 126, 253-7	56
1185	Pharmacologic modelling of Alzheimer's disease. 1986 , 10, 599-610	91
1184	Prenatal development of nucleus basalis complex and related fiber systems in man: a histochemical study. 1986 , 17, 1047-77	130
1183	Cholinergic function and intellectual decline in Alzheimer's disease. 1986 , 19, 1-28	649
1182	Positron emission tomography and the possible origins of cytopathology in Alzheimer's disease. 1986 , 10, 501-18	9
1181	Nicotinic acetylcholine binding sites in Alzheimer's disease. 1986 , 371, 146-51	510
1180	Acetylcholine, aging and anatomy: differential effects in the hippocampus. 1986 , 362, 157-60	37
1179	The effects of physostigmine and scopolamine on recognition memory in monkeys. 1986 , 45, 81-7	190
1178	Scopolamine effects on memory retention in mice: a model of dementia?. 1986 , 45, 169-84	164

1177	Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. 1986 , 45, 196-211	214
1176	Neurotransmitter precursors and brain function. 1986 , 38, 54-71	3
1175	The current status of the cortical cholinergic system in Alzheimer's disease and Parkinson's disease. 1986 , 70, 105-32	33
1174	Behavioral and biochemical effects of nucleus basalis magnocellularis lesions: implications and possible relevance to understanding or treating Alzheimer's disease. 1986 , 70, 345-61	28
1173	Comparative neuropsychology of cortical and subcortical dementia. 1986 , 13, 410-4	30
1172	Effects of oral physostigmine and lecithin on memory and attention in closed head-injured patients. 1986 , 3, 333-42	53
1171	Routine care and psychosocial support of the patient with the acquired immunodeficiency syndrome. 1986 , 70, 707-20	22
1170	[Cerebral glucose metabolism in presenile dementia of the Alzheimer type--follow-up of therapy with muscarinic choline agonists]. 1986 , 54, 364-73	27
1169	Dietary choline augments associative memory function in <i>Limax maximus</i> . 1986 , 17, 113-20	10
1168	Systematic regional differences in the cholinergic innervation of the primate cerebral cortex: distribution of enzyme activities and some behavioral implications. 1986 , 19, 144-51	128
1167	Ultrastructural organization of choline-acetyltransferase-immunoreactive fibres innervating the neocortex from embryonic ventral forebrain grafts. 1986 , 250, 192-205	124
1166	Reactive synaptogenesis in hippocampal area CA1 of aged and young adult rats. 1986 , 252, 374-84	45
1165	Sex differences in muscarinic receptor binding after chronic ethanol administration in the rat. 1986 , 90, 537-42	19
1164	The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance. 1986 , 89, 347-54	52
1163	Scopolamine and the control of attention in humans. 1986 , 89, 94-7	100
1162	Effects of physostigmine on memory test performance in normal volunteers. 1986 , 90, 364-6	7
1161	Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. 1986 , 46, 288-93	243
1160	Vinpocetine: nootropic effects on scopolamine-induced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats. 1986 , 24, 1123-8	75

1159	Cerebral embolization impairs memory function and reduces cholinergic marker enzyme activities in various brain regions in rats. 1986 , 24, 1729-31	17
1158	Aluminum impairs glucose utilization and cholinergic activity in rat brain in vitro. 1986 , 40, 93-102	64
1157	New perspectives on Alzheimer's disease. 1986 , 9, 489-512	338
1156	Cholinergic dysfunction in Alzheimer disease: cause or effect?. 1986 , 65, 91-103	14
1155	Alzheimer's disease. 1986 , 314, 964-73	838
1154	The cholinergic neurotransmitter system in human memory and dementia: a review. 1986 , 38, 535-73	133
1153	Differential patterns of memory loss among patients with Alzheimer's disease, Huntington's disease, and alcoholic Korsakoff's syndrome. <i>Archives of Neurology</i> , 1986 , 43, 239-46	307
1152	Changes in the human visual evoked potential caused by the anticholinergic agent hyoscine hydrobromide: comparison with results in Alzheimer's disease. 1986 , 49, 175-82	55
1151	Learning and memory impairment with benzhexol. 1987 , 21, 612-4	4
1150	Wechsler Intelligence Scale profiles, the cholinergic system, and Alzheimer's disease. 1987 , 9, 180-6	25
1149	WAIS-R marker for dementia of the Alzheimer type? An empirical and statistical induction test. 1987 , 9, 767-74	22
1148	Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. 1987 , 44, 418-26	264
1147	Central cholinergic systems and the P3 evoked potential. 1987 , 33, 199-205	61
1146	Neurotransmitters and memory: Role of cholinergic, serotonergic, and noradrenergic systems.. 1987 , 101, 325-332	132
1145	Lithium and memory: a review. 1987 , 32, 312-6	24
1144	Some Psychophysiological and Pharmacological Correlates of A Developmental, Cognitive, and Motivational Theory. 1987 , 83-179	
1143	Characteristics of memory impairment following lesioning of the basal forebrain and medial septal nucleus in rats. 1987 , 419, 19-31	182
1142	Blockade of cholinergic receptors by an irreversible antagonist, propylbenzylcholine mustard (PrBCM), in the rat cerebral cortex causes deficits in passive avoidance learning. 1987 , 400, 53-61	18

1141	Effect of cholinergic deficit induced by ethylcholine aziridinium (AF64A) on noradrenergic and dopaminergic parameters in rat brain. 1987 , 421, 75-84	51
1140	RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. 1987 , 22, 1067-78	78
1139	Met-enkephalin, age and anatomy: a microiontophoretic study in the hippocampus. 1987 , 40, 203-13	6
1138	The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. 1987 , 434, 423-38	293
1137	Near-total loss of 'learning' and 'memory' as a result of combined cholinergic and serotonergic blockade in the rat. 1987 , 23, 43-57	167
1136	Agonist and antagonist binding to rat brain muscarinic receptors: influence of aging. 1987 , 8, 115-22	54
1135	Cholinergic Treatment in Alzheimer's Disease: Encouraging Results. 1987 , 329, 139-141	1
1134	Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: forebrain. 1987 , 20, 65-107	107
1133	Sensory, motor and cognitive alterations in aged cats. 1987 , 8, 253-63	35
1132	Behavioural, biochemical and histochemical effects of different neurotoxic amino acids injected into nucleus basalis magnocellularis of rats. 1987 , 20, 653-69	322
1131	Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. 1987 , 92, 292-300	98
1130	Effects of vinpocetine in scopolamine-induced learning and memory impairments. 1987 , 11, 29-36	15
1129	The origins of cholinergic and other subcortical afferents to the thalamus in the rat. 1987 , 262, 105-24	498
1128	Cholinergic-dependent cognitive deficits in Parkinson's disease. 1987 , 22, 26-30	126
1127	Age-related shrinkage of cortically projecting cholinergic neurons: a selective effect. 1987 , 22, 31-6	98
1126	Effect of pyroglutamic acid stereoisomers on ECS and scopolamine-induced memory disruption and brain acetylcholine levels in the rat. 1987 , 19, 901-12	18
1125	Effects of age on antidepressant kinetics and memory in Fischer 344 rats. 1987 , 26, 313-9	9
1124	Neurochemical and behavioral effects of N-ethyl-acetylcholine aziridinium chloride in mice. 1987 , 26, 365-71	11

1123	Characteristics of memory impairment in cerebral embolized rats at the chronic stage. 1987 , 28, 243-9	5
1122	Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. 1987 , 27, 491-5	98
1121	Dental implications of pharmacological management of the Alzheimer's patient. 1987 , 6, 59-66	12
1120	Surgery and the patient with Alzheimer's disease. 1988 , 9, 227-9	2
1119	Cognitive deficits in olivopontocerebellar atrophy: implications for the cholinergic hypothesis of Alzheimer's dementia. 1988 , 24, 200-6	137
1118	Brain acetylcholinesterase after acute parathion poisoning: a comparative quantitative histochemical analysis post mortem. 1988 , 24, 252-7	23
1117	Age-related sex differences in verbal memory. 1988 , 44, 403-11	196
1116	An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg s.c. 1988 , 3, 27-41	85
1115	Preventive effect of cholecystinin octapeptide on scopolamine-induced memory impairment in the rat. 1988 , 12, 63-70	27
1114	Mechanisms of cholinesterase inhibition in senile dementia of the alzheimer type: Clinical, pharmacological, and therapeutic aspects. 1988 , 12, 163-195	167
1113	Cognitive functions affected by scopolamine in alzheimer's disease and normal aging. 1988 , 12, 271-278	25
1112	Prevention of scopolamine effect on the decrease of acetylcholine content by peripherally administered cholecystinin octapeptide in some regions of the rat brain. 1988 , 14, 67-74	3
1111	Ascending projections from the pedunculopontine tegmental nucleus and the adjacent mesopontine tegmentum in the rat. 1988 , 274, 483-515	298
1110	Basal forebrain efferents to the medial dorsal thalamic nucleus in the rhesus monkey. 1988 , 277, 365-90	53
1109	Dissociative effects of scopolamine on working memory in healthy young volunteers. 1988 , 96, 487-92	38
1108	CNS involvement in acute organophosphate poisoning: specific pattern of toxicity, clinical correlates and antidotal treatment. 1988 , 9, 437-46	13
1107	Effects of aging on the interaction of quinuclidinyl benzilate, N-methylscopolamine, pirenzepine, and gallamine with brain muscarinic receptors. 1988 , 13, 1183-91	24
1106	Antidepressants and human memory: an investigation of four drugs with different sedative and anticholinergic profiles. 1988 , 95, 520-7	58

1105	Effects of lorazepam on memory, attention and sedation in man. 1988 , 95, 208-15	53
1104	Modulation of memory by post-training epinephrine: involvement of cholinergic mechanisms. 1988 , 94, 379-85	46
1103	The effects of scopolamine on working memory in healthy young volunteers. 1988 , 96, 145-52	88
1102	Age-related scopolamine effects on social and individual behaviour in rats. 1988 , 95, 344-50	20
1101	Physostigmine accelerates the development of associative memory processes in the infant rat. 1988 , 95, 401-6	6
1100	Attenuation of scopolamine-induced amnesia in mice. 1988 , 96, 417-20	76
1099	Scopolamine reduces frontal cortex perfusion. 1988 , 8, 635-41	63
1098	An evaluation of the mechanism of scopolamine-induced impairment in two passive avoidance protocols. 1988 , 29, 15-21	84
1097	A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. 1988 , 31, 141-7	70
1096	Electrical stimulation of the human hippocampus produces verbal intrusions during memory testing. 1988 , 26, 623-7	22
1095	Acute scopolamine treatment decreases dopamine metabolism in rat hippocampus and frontal cortex. 1988 , 149, 367-70	30
1094	Radial-arm maze deficits produced by colchicine administered into the area of the nucleus basalis are ameliorated by cholinergic agents. 1988 , 438, 83-94	78
1093	Cholinergic grafts in the neocortex or hippocampus of aged rats: reduction of delay-dependent deficits in the delayed non-matching to position task. 1988 , 102, 57-64	99
1092	Scopolamine amnesia of passive avoidance: a deficit of information acquisition. 1988 , 50, 255-74	109
1091	Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. 1988 , 111 (Pt 5), 1079-110	248
1090	Differential responsivity of mood, behavior and cognition to cholinergic agents in elderly neuropsychiatric populations. 1988 , 13, 371-389	72
1089	Animal models of Alzheimer's disease: experimental cholinergic denervation. 1988 , 472, 103-18	301
1088	Treatment strategies for senile dementia: antagonist beta-carbolines. 1988 , 11, 13-7	96

1087	Long-term potentiation: persisting problems and recent results. 1988 , 21, 363-72	74
1086	Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. 1988 , 13, 345-57	630
1085	Age-related reduction in responses of rat hippocampal neurons to locally applied monoamines. 1988 , 9, 173-9	36
1084	Muscarinic antagonist enhances one-trial food-aversion learning in the mollusc Pleurobranchaea. 1988 , 21, 169-79	12
1083	The effect of chronic ethanol consumption on muscarinic receptors in rat brain. 1988 , 12, 447-52	13
1082	Recent advances in the understanding of dementia. 1988 , 64, 99-106	1
1081	Drug-induced alzheimerism. <i>Archives of Neurology</i> , 1988 , 45, 356-7	15
1080	Handbook of Psychopharmacology. 1988 ,	1
1079	Absence of anticholinergic activity of rolipram, an antidepressant with a novel mechanism of action, in three different animal models in vivo. 1988 , 21, 218-21	15
1078	Effects of pyritinol on the distribution of electrical brain activity. 1988 , 21, 343-5	9
1077	The effects of acute scopolamine in geriatric depression. 1988 , 45, 906-12	52
1076	The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man. 1988 , 2, 67-79	37
1075	Cholinergic modulation of human limbic evoked potentials. 1988 , 38, 407-14	10
1074	What Is a Complete Work-up for Dementia?. 1988 , 4, 163-180	1
1073	Cognitive enhancing agents: current status in the treatment of Alzheimer's disease. 1988 , 15, 249-56	14
1072	Drug Treatments of Dementia. 1989 , 155, 595-611	16
1071	Single-photon emission computed tomography studies with ^{99m} Tc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine. 1989 , 29, 261-5	34
1070	Cognitive differences between patients with progressive supranuclear palsy and Alzheimer's disease. 1989 , 11, 605-14	31

1069	Cholinergic and serotonergic effects on the P3 potential and recent memory. 1989 , 11, 252-60	59
1068	A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. <i>Archives of Neurology</i> , 1989 , 46, 141-5	252
1067	A Dictionary of Neuropsychology. 1989 ,	7
1066	Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice. 1989 , 34, 129-37	56
1065	Blockade of ACh receptors by PrBCM causes deficits in shuttle avoidance performance. 1989 , 33, 895-8	1
1064	Glucose enhancement of performance on memory tests in young and aged humans. 1989 , 27, 1129-38	205
1063	Human memory: psychology, pathology and pharmacology. 1989 , 3, 451-471	1
1062	Cholinergic innervation of the monkey amygdala: an immunohistochemical analysis with antisera to choline acetyltransferase. 1989 , 281, 337-61	133
1061	Neurochemical effects of pyritinol and their relevance for the treatment of brain function deficits in old age. 1989 , 18, 1-9	3
1060	Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. 1989 , 99, 129-33	31
1059	Neuronal membrane depolarization and the control of cholinergic muscarinic receptors: selective effect on different neuronal cell types. 1989 , 9, 87-94	3
1058	Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?. 1989 , 13 Suppl, S47-59	3
1057	Autoradiographic studies on the effect of ethanol on muscarinic receptors in rat brain. 1989 , 15, 91-5	
1056	An atlas of the regional and laminar distribution of choline acetyltransferase immunoreactivity in rat cerebral cortex. 1989 , 28, 291-336	215
1055	Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results. 1989 , 43, 487-91	22
1054	Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. 1989 , 33, 469-81	176
1053	Nerve growth factor as a potential treatment in Alzheimer's disease. 1989 , 43, 483-5	7
1052	Long-term acetyl-L-carnitine preserves spatial learning in the senescent rat. 1989 , 13, 237-45	25

1051	Nootropic drugs and brain cholinergic mechanisms. 1989 , 13 Suppl, S77-88	42
1050	Effects of combined muscarinic and nicotinic blockade on choice accuracy in the radial-arm maze. 1989 , 51, 270-7	65
1049	Effects of idebenone on the levels of acetylcholine, choline, free fatty acids, and energy metabolites in the brains of rats with cerebral ischemia. 1989 , 8, 247-56	18
1048	The basal nucleus of Meynert revised: the nerve cell number decreases with age. 1989 , 8, 21-7	51
1047	Effects of cholinergic drugs on learning impairment in ventral globus pallidus-lesioned rats. 1989 , 90, 1-21	47
1046	Effect of anticholinergic drug on long-term potentiation in rat hippocampal slices. 1989 , 482, 194-7	103
1045	Pre-clinical evaluation of cognition enhancing drugs. 1989 , 13 Suppl, S99-115	24
1044	Age-related changes in multiple neurotransmitter systems in the monkey brain. 1989 , 10, 11-9	196
1043	The role of perseveration in language disorders. 1989 , 4, 471-478	5
1042	Cognitive enhancers: potential strategies and experimental results. 1989 , 13 Suppl, S117-39	14
1041	Acquired cognitive disorders of the elderly. 1989 , 73, 1383-411	8
1040	Distinct memory impairments following electroconvulsive therapy and imipramine. 1989 , 19, 111-9	31
1039	The cholinergic receptor system of the human brain: neurochemical and pharmacological aspects in aging and Alzheimer. 1989 , 79, 335-43	32
1038	Association of sleep parameters and memory in intact old rats and young rats with lesions in the nucleus basalis magnocellularis.. 1989 , 103, 755-764	35
1037	Age differences in learning serial patterns: Direct versus indirect measures.. 1989 , 4, 357-364	188
1036	Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease. 1990 , 38, 113-22	21
1035	Long-lasting facilitation of excitatory postsynaptic potentials in the rat hippocampus by acetylcholine. 1990 , 427, 381-93	168
1034	Human brain cholinergic pathways. 1990 , 84, 231-41	40

1033	Effect of a novel CNS-selective cholinesterase inhibitor, SM-10888, on habituation and passive avoidance responses in mice. 1990 , 53, 211-20	12
1032	Pharmacological and biochemical assessment of SM-10888, a novel cholinesterase inhibitor. 1990 , 53, 145-55	14
1031	Antimuscarinic drugs in the treatment of movement disorders. 1990 , 84, 389-97	25
1030	Neuronal plasticity in normal aging and deficient plasticity in Alzheimer's disease: a proposed intercellular signal cascade. 1990 , 86, 75-87	18
1029	Neural Transplantation in Animal Models of Dementia. 1990 , 2, 567-587	113
1028	Effects of physostigmine on operant serial discrimination/reversal learning in rats. 1990 , 37, 155-60	4
1027	Low dose tetrahydroaminoacridine (THA) improves cognitive function but does not affect brain acetylcholine in rats. 1990 , 36, 291-8	37
1026	Post-ictal recognition memory predicts laterality of temporal lobe seizure focus: comparison with post-operative data. 1990 , 28, 957-67	33
1025	Application of a brain-targeting chemical delivery system to 9-amino-1,2,3,4-tetrahydroacridine. 1990 , 7, 658-64	13
1024	Anticholinergic serum levels and cognitive performance. 1990 , 240, 28-33	35
1023	Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. 1990 , 100, 243-50	101
1022	Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine. 1990 , 5, 213-23	108
1021	Hypothesis linking plasticity, vulnerability and nerve growth factor to basal forebrain cholinergic neurons. 1990 , 5, 223-231	5
1020	Distribution of 125I-neurotensin binding sites in human forebrain: comparison with the localization of acetylcholinesterase. 1990 , 297, 487-98	25
1019	Influences of cholecystokinin and analogues on memory processes. 1990 , 21, 257-276	60
1018	Study of the potential pharmacodynamic antagonism of RU 41 656 on scopolamine and triazolam impairment in healthy subjects. 1990 , 5, 323-337	3
1017	Neurochemical aspects on aging and diseases with cognitive impairment. 1990 , 27, 541-7	95
1016	Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). 1990 , 27, 569-75	83

1015	Intrusion Errors in Patients with Degenerative or Vascular Dementia: The Cholinergic Connection?. 1990 , 1, 202-207	1
1014	A WAIS-R marker for accelerated aging and dementia, Alzheimer's type? Base rates of the Fuld formula in the WAIS-R standardization sample. 1990 , 12, 759-65	10
1013	Antidepressant effect on memory in depressed older persons. 1990 , 12, 655-63	13
1012	Scopolamine and sustained retrieval from semantic memory. 1990 , 4, 13-8	10
1011	Relationship of normal serum vitamin B12 and folate levels to cognitive test performance in subtypes of geriatric major depression. 1990 , 3, 98-105	23
1010	Poor blood glucose regulation predicts sleep and memory deficits in normal aged rats. 1990 , 45, B169-73	37
1009	Intracerebroventricular bethanechol for Alzheimer's disease. Variable dose-related responses. <i>Archives of Neurology</i> , 1990 , 47, 1025-30	20
1008	Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial. 1990 , 3, 13-6	10
1007	The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. 1990 , 4, 219-32	28
1006	Behavioural effects of chronic manipulations of dietary choline in senescent rats. 1990 , 14, 949-60	6
1005	Attenuation of serotonin-induced suppression of [(3)H]acetylcholine release from rat cerebral cortex by minaprine: Possible involvement of the serotonin-2 receptor and K(+) channel. 1990 , 16, 301-7	12
1004	Effect of aging on NADPH-diaphorase neurons in laterodorsal tegmental nucleus and striatum of mice. 1990 , 11, 185-92	35
1003	Markers for biogenic amines in the aged rat brain: relationship to decline in spatial learning ability. 1990 , 11, 507-14	144
1002	Regional changes in NGF receptor immunohistochemical labeling in the septum of the aged rat. 1990 , 11, 481-4	38
1001	Electrophysiological characteristics of cholinergic and non-cholinergic neurons in the rat medial septum-diagonal band complex. 1990 , 513, 171-4	89
1000	Nucleus basalis magnocellularis and memory: differential effects of two neurotoxins. 1990 , 54, 13-26	65
999	The effects of ibotenic acid lesions of the nucleus basalis and cholinergic-rich neural transplants on win-stay/lose-shift and win-shift/lose-stay performance in the rat. 1990 , 36, 229-49	124
998	Interaction of aluminum ions with phosphoinositide metabolism in rat cerebral cortical membranes. 1991 , 49, 1245-52	9

997	Diagnostic and pharmacological approaches in Alzheimer's disease. 1991 , 1, 144-62	21
996	Phosphatidylserine reverses the age-dependent decrease in cortical acetylcholine release: a microdialysis study. 1991 , 194, 11-6	82
995	A longitudinal study of cerebrospinal fluid acetylcholinesterase in delirium: changes at the acute stage and at one-year followup. 1991 , 38, 135-42	5
994	Cerebral structure on MRI, Part I: Localization of age-related changes. 1991 , 29, 55-67	258
993	Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. 1991 , 11, 3218-26	805
992	Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease. 1991 , 158, 558-62	11
991	WITHDRAWN: Memory Changes with Age: Neurobiological Correlates. 1991 , 259-296	4
990	NIK-247 Blocks Voltage-Dependent Ionic Currents in Crayfish Axon. 1991 , 57, 545-552	1
989	Pharmacologic Models of Alzheimer's Disease. 1991 , 14, 287-308	18
988	The Treatment of Cognitive Impairment in Alzheimer's Disease: Beyond the Cholinergic Approach. 1991 , 14, 461-482	14
987	Disturbance of learning and memory by the alkylation of muscarinic acetylcholine receptors by propylbenzilylcholine mustard. 1991 , 37 Suppl 1, 12-6	1
986	Memory storage and effect of repeated treatment with a new antidepressant drug: rubidium chloride. 1991 , 19, 395-402	7
985	Cholinesterase inhibition in the scopolamine model of dementia. 1991 , 640, 268-71	47
984	Effects of NMDA modulation in scopolamine dementia. 1991 , 640, 241-4	66
983	Cholinergic deafferentation after focal cerebral infarct in rats. 1991 , 22, 1291-6	128
982	NIK-247 blocks voltage-dependent ionic currents in crayfish axon. 1991 , 57, 545-52	6
981	Cerebrospinal fluid acetylcholinesterase in patients with dementia associated with schizophrenia or chronic alcoholism. 1991 , 83, 441-3	10
980	[Syndrome of partial cholinergic deafferentation of the cortical mantle--a concept for describing the brain-behavior relationship in dementia diseases]. 1991 , 59, 81-91	9

979	The cellular basis of delirium and its relevance to age-related disorders including Alzheimer's disease. 1991 , 3, 373-95	59
978	Unaware learning versus preserved learning in pharmacologic amnesia: Similarities and differences.. 1991 , 17, 1017-1029	81
977	1-Alkyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyl-oximes: a new class of potent orally active muscarinic agonists related to arecoline. 1991 , 26, 853-868	28
976	High-affinity [3H]THA (tetrahydroaminoacridine) binding sites in rat brain. 1991 , 8, 200-3	5
975	Biochemical and behavioral characterization of a novel cholinergic agonist, SR 95639. 1991 , 39, 287-92	3
974	A comparison of the effects of scopolamine and diazepam on working memory. 1991 , 105, 442-5	44
973	Distinguishing between attentional and amnesic effects in information processing: the separate and combined effects of scopolamine and nicotine on verbal free recall. 1991 , 104, 363-6	33
972	Transient impairment of recognition memory following ibotenic-acid lesions of the basal forebrain in macaques. 1991 , 86, 18-26	53
971	RU 41,656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers. 1991 , 41, 225-31	7
970	A new assessment tool for neuropsychopharmacologic research: the Computerized Neuropsychological Test Battery. 1991 , 4, 211-7	24
969	The effects of scopolamine on retrieval from semantic memory. 1991 , 5, 234-7	7
968	Seminars in medicine of the Beth Israel Hospital, Boston. beta-Amyloid and the pathogenesis of Alzheimer's disease. 1991 , 325, 1849-57	185
967	Cholinergic neurons of the central nervous system: morphofunctional aspects. 1991 , 366, 7-13	11
966	Cholinergic 'blockade' as a model of the cognitive deficits in Alzheimer's disease. 1992 , 115 (Pt 6), 1681-99	65
965	Amnesia following a discrete basal forebrain lesion. 1992 , 115 (Pt 6), 1827-47	245
964	Implicit and explicit memory in young, old, and demented adults. 1992 , 14, 298-316	29
963	Risk Factors for Delirium in Hospitalized Elderly. 1992 , 267, 827	280
962	Selective attention skills in Alzheimer's disease: performance on graded cancellation tests varying in density and complexity. 1992 , 47, P146-53	24

961	The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers. 1992 , 6, 489-500	18
960	Central anticholinergic hypersensitivity in aging. 1992 , 5, 72-7	54
959	Primacy and recency effects in the assessment of memory using the rey auditory verbal learning test. 1992 , 7, 97-107	9
958	A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. 1992 , 327, 1253-9	546
957	References. 1992 , 95, 327-347	
956	The inositol 1,4,5-trisphosphate pathway mediates cholinergic potentiation of rat hippocampal neuronal responses to NMDA. 1992 , 447, 513-33	142
955	The effect of a single low dose of trihexyphenidyl on memory functioning in the healthy elderly. 1992 , 4, 207-14	9
954	Medication effects: Conceptual and methodological issues in schizophrenia research. 1992 , 12, 345-361	47
953	Scopolamine-induced amnesia in humans: lack of effects of the benzodiazepine receptor antagonist α -carboline ZK 93426. 1992 , 6, 382-8	5
952	Effect of piracetam administration on 3H-N-methylscopolamine binding in cerebral cortex of young and old rats. 1992 , 50, 971-7	7
951	Memory-modulatory effects of centrally acting noradrenergic drugs: possible involvement of brain cholinergic mechanisms. 1992 , 57, 248-55	28
950	Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. 1992 , 17, 215-26	162
949	Attempts to make models for Alzheimer's disease. 1992 , 13, 237-55	16
948	Animal and drug modelling for Alzheimer synaptic pathology. 1992 , 39, 517-45	39
947	Effects of oxiracetam on neurotransmitter release from rat hippocampus slices and synaptosomes. 1992 , 145, 109-13	14
946	Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. 1992 , 13, 313-8	58
945	Convergent cholinergic activities in aging and Alzheimer's disease. 1992 , 13, 393-400	156
944	Anticholinergic drug effects on quantitative electroencephalogram, visual evoked potential, and verbal memory. 1992 , 31, 600-6	64

943	Cholinergic toxins and Alzheimer's disease. 1992 , 648, 63-70	13
942	Cholinergic activity and constraints on information processing. 1992 , 33, 1-22	40
941	Primacy and recency effects in the assessment of memory using the rey auditory verbal learning test. 1992 , 7, 97-107	
940	[3H]linopirdine (DuP 996) labels a novel binding site in rat brain involved in the enhancement of stimulus-induced neurotransmitter release: autoradiographic localization studies. 1992 , 582, 335-41	12
939	Regulation of acetylcholine release in vivo from rat hippocampus by monoamines as revealed by novel column-switching HPLC with electrochemical detection. 1992 , 572, 340-4	27
938	Reversal of learning and memory impairments following lesion of the nucleus basalis magnocellularis (NBM) by concurrent noradrenergic depletion using DSP4 in the rat. 1992 , 595, 327-33	16
937	L-alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. 1992 , 211, 351-8	44
936	Circulating suppressing factor for the muscarinic acetylcholine receptor in patients with senile dementia of the Alzheimer type. 1992 , 38 Suppl 1, 24-8	3
935	Nucleus basalis lesions attenuate acquisition, but not retention, of Pavlovian heart rate conditioning and have no effect on eyeblink conditioning. 1992 , 89, 501-10	9
934	Cholinomimetics and Alzheimer's disease. 1992 , 2, 777-780	16
933	Alzheimer's dementia produces a loss of discrimination but no increase in rate of memory decay in delayed matching to sample. 1992 , 30, 133-43	34
932	Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. 1992 , 42, 75-83	58
931	Hypersensitivity to scopolamine in the elderly. 1992 , 107, 437-41	84
930	Acute nicotinic blockade produces cognitive impairment in normal humans. 1992 , 108, 480-4	125
929	Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. 1992 , 106, 26-30	85
928	Brain and cerebrospinal fluid cholinesterases in Alzheimer's disease, Parkinson's disease and aging. A critical review of clinical and experimental studies. 1992 , 4, 337-58	11
927	Cholinergic mechanisms in physical dependence on barbiturates, ethanol and benzodiazepines. 1992 , 88, 199-221	33
926	Effects of chronic treatment with L-alpha-glycerylphosphorylcholine on hippocampal cholinergic transmission in the rat. 1992 , 27, 277-286	1

925	The role of two major cholinergic systems in memory acquisition and retention in the eight-arm radial maze. 1992 , 7, 173-181	3
924	¹⁴ C-labeling of a tetrahydroacridine, a novel CNS-selective cholinesterase inhibitor. 1992 , 31, 553-560	2
923	A double-blind, placebo-controlled study of the effects of eptastigmine on scopolamine-induced cognitive deficits in healthy male subjects. 1993 , 8, 271-278	9
922	Autoradiographic comparison of cholinergic and other transmitter receptors in the normal human hippocampus. 1993 , 3, 307-15	54
921	Cognitive impairment in schizophrenia: how experimental models using nonhuman primates may assist improved drug therapy for negative symptoms. 1993 , 31, 1133-46	4
920	Effects of acute doses of oxiracetam in the scopolamine model of human amnesia. 1993 , 110, 421-6	18
919	Time gradient for post-test vulnerability to scopolamine-induced amnesia following the initial acquisition session of a spatial reference memory task in mice. 1993 , 60, 139-51	16
918	Facilitation of memory storage by the acetylcholine M2 muscarinic receptor antagonist AF-DX 116. 1993 , 60, 69-74	26
917	Recovery of choline acetyltransferase activity without sprouting of the residual acetylcholine innervation in adult rat cerebral cortex after lesion of the nucleus basalis. 1993 , 630, 195-206	34
916	Noradrenergic and cholinergic interactions in the amygdala and the modulation of memory storage. 1993 , 58, 167-74	72
915	A primate model of Alzheimer's disease. 1993 , 57, 117-22	43
914	The role of galanin in cholinergically-mediated memory processes. 1993 , 17, 71-85	12
913	Increased responsiveness of hippocampal pyramidal neurons to nicotine in aged, learning-impaired rats. 1993 , 14, 259-66	22
912	Analysis of verbal memory and learning by means of selective reminding procedure in Alzheimer and multi-infarct dementias. 1993 , 5, 185-92	
911	Is Alzheimer's disease related to a deficit or malfunction of rapid eye movement (REM) sleep?. 1993 , 41, 435-9	104
910	General overview: past contributions and future opportunities using aged nonhuman primates. 1993 , 14, 711-4	5
909	Continuous ICV infusion of scopolamine impairs sustained attention of rhesus monkeys. 1993 , 14, 147-51	45
908	Muscarinic depression of synaptic transmission and blockade of norepinephrine-induced long-lasting potentiation in the dentate gyrus. 1993 , 54, 377-89	10

907	Abnormalities in muscarinic cholinergic receptors and their G-protein coupling systems in the cerebral frontal cortex in Alzheimer's disease. 1993 , 17, 77-89	8
906	Metabolic and cognitive changes in hereditary ataxia. 1993 , 119, 134-40	20
905	The role of cholinergic systems in visuospatial processing and memory. 1993 , 15, 832-42	58
904	Memory and cognitive impairments in a case of long-term trihexyphenidyl abuse. 1993 , 26, 59-62	6
903	Blood-brain barrier penetration and in vivo activity of an NGF conjugate. 1993 , 259, 373-7	268
902	Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia. 1993 , 98, 413-20	108
901	Learning and memory in monozygotic twins discordant for schizophrenia. 1993 , 23, 71-85	174
900	Further evidence that scopolamine can improve verbal fluency. 1993 , 7, 159-63	5
899	Tacrine for Alzheimer's Disease: A More Definitive Report. 1993 , 6, 59-60	
898	Clinical aspects of cholinergic pharmacology. 1993 , 98, 421-2	1
897	Disruption of human eyeblink conditioning after central cholinergic blockade with scopolamine.. 1993 , 107, 271-279	75
896	Intraventricular galanin impairs delayed nonmatching-to-sample performance in rats.. 1993 , 107, 458-467	78
895	Drug-induced amnesia: implications for cognitive neuropsychological investigations of memory. 1993 , 114, 477-93	41
894	The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. 1993 , 162, 43-8	243
893	Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 11816-20	11,5 108
892	Muscarinic cholinergic receptor subtypes in the rat frontoparietal cortex after ipsilateral lesions of the nucleus basalis magnocellularis. 1993 , 46, 301-7	7
891	Cholinergic blockade and human information processing: are we asking the right questions?. 1994 , 8, 54-9	12
890	A double FDG/PET study of the effects of scopolamine in older adults. 1994 , 10, 191-8	25

- 889 Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. **1994**, 10, 93-107 118
- 888 Serial pattern learning after head injury. **1994**, 16, 271-88 14
- 887 A long-term follow-up study of cerebrospinal fluid acetylcholinesterase in delirium. **1994**, 243, 347-51 8
- 886 Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin?. **1994**, 114, 539-50 89
- 885 An acute effect of triazolam on muscarinic cholinergic receptor binding in the human brain measured by positron emission tomography. **1994**, 113, 311-7 13
- 884 The metabolic brain pattern of young subjects given scopolamine. **1994**, 100, 133-43 14
- 883 Dialkylaminoalkyl esters of 2,2-diphenyl-2-alkylthioacetic acids: a new class of potent and functionally selective muscarinic antagonists. **1994**, 2, 1061-74 5
- 882 Visual evoked potentials to flash and pattern reversal stimulation after administration of systemic or topical scopolamine. **1994**, 86, 311-22 12
- 881 Effects of nicotine on levels of acetylcholine and biogenic amines in rat cortex. **1994**, 31, 108-119 23
- 880 Blood glucose influences memory and attention in young adults. **1994**, 32, 595-607 189
- 879 Effects of a novel compound MCI-225 on impaired learning and memory in rats. **1994**, 48, 345-9 11
- 878 In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog. **1994**, 667, 278-82 50
- 877 Reduced choline acetyltransferase activity and muscarinic M1 receptor levels in aged Fisher 344 rat brains did not parallel their respective mRNA levels. **1994**, 658, 87-92 20
- 876 Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. **1994**, 123, 44-51 23
- 875 Cortical and subcortical neuropeptides in Alzheimer's disease. **1994**, 15, 589-95 19
- 874 New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment. **1994**, 717, 16-32 43
- 873 Estrogen and nerve growth factor-related systems in brain. Effects on basal forebrain cholinergic neurons and implications for learning and memory processes and aging. **1994**, 743, 165-96; discussion 197-9 112
- 872 Presynaptic cholinergic modulators as potent cognition enhancers and analgesic drugs. 1. Tropic and 2-phenylpropionic acid esters. **1994**, 37, 1704-11 31

871	Effects of a single intravenous dose of scopolamine on the quantitative EEG in Alzheimer's disease patients and age-matched controls. 1994 , 91, 407-12	28
870	Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography. 1994 , 635, 196-202	26
869	Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain. 1994 , 655, 153-60	11
868	Visual discrimination and P300 are affected in parallel by cholinergic agents in the behaving monkey. 1994 , 56, 161-6	13
867	Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers. 1994 , 18, 133-9	6
866	Muscarinic cholinergic receptors in the hippocampus of aged rats: influence of choline alphoscerate treatment. 1994 , 76, 49-64	12
865	Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis. 1994 , 55, 2037-49	53
864	Memory disorders: novel treatments, clinical perspective. 1994 , 55, 2189-94	10
863	Developmental regulation of adult cortical morphology and behavior: an animal model for mental retardation. 1994 , 12, 239-53	38
862	Neuropathobiology of senile dementia and mechanism of action of nootropic drugs. 1994 , 4, 285-303	12
861	Effects of cholinergic blockade on language in healthy young women. Implications for the cholinergic hypothesis in dementia of the Alzheimer type. 1994 , 117 (Pt 6), 1377-84	51
860	Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. 1994 , 41, 361-71	216
859	The central cholinergic system during aging. 1994 , 100, 67-71	41
858	Selective immunotoxic lesions of basal forebrain cholinergic cells: Effects on learning and memory in rats.. 1995 , 109, 714-722	282
857	Identity negative priming in older adults and individuals with dementia of the Alzheimer type.. 1995 , 9, 537-555	59
856	Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease. 1995 , 6, 245-51	2
855	The clinical profiles, recovery, and rehabilitation of memory disorders. 1995 , 5, 141-59	1
854	Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. 1995 , 15, 3-31	171

853	Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. 1995 , 58, 299-309	52
852	The efficacy of cholinergic drugs in patients with Alzheimer's disease—focus on the aminoacridines. 1995 , 10, 89-96	4
851	Alzheimer's disease: Tacrine and tacrine metabolite concentrations in plasma and cognitive change. 1995 , 34, 55-65	2
850	Scopolamine and lorazepam exert different patterns of effects in a test battery assessing stages of information processing. 1995 , 119, 315-24	22
849	Effects of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on the dopaminergic and cholinergic receptors as evaluated by positron emission tomography in the Rhesus monkey. 1995 , 102, 189-208	6
848	Cholinergic projections to the anterior thalamic nuclei in the rat: a combined retrograde tracing and choline acetyl transferase immunohistochemical study. 1995 , 192, 335-49	20
847	The effect of the muscarinic antagonist scopolamine on regional cerebral blood flow during the performance of a memory task. 1995 , 104, 337-48	43
846	Food for thought. 1995 , 1, 1006-7	
845	AF150(S): a new functionally selective M1 agonist improves cognitive performance in rats. 1995 , 51, 667-74	33
844	The cholinergic contribution to neuromodulation in the cerebral cortex. 1995 , 7, 297-307	26
843	Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. 1995 , 6, 99-107	26
842	Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. 1995 , 15, 4077-92	364
841	Synergistic anticholinergic and antiserotonergic effects in humans. 1995 , 17, 611-21	17
840	Chronic postinjury administration of MDL 26,479 (Suritazole), a negative modulator at the GABAA receptor, and cognitive impairment in rats following traumatic brain injury. 1995 , 83, 878-83	27
839	Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease. 1995 , 155, 1766	31
838	The treatment of Alzheimer's disease. 1995 , 9, 43-56	24
837	Ageing: the cholinergic hypothesis of cognitive decline. 1995 , 5, 161-8	176
836	Comparative tissue distribution of conformationally restricted radioiodinated vesamicol receptor ligands. 1995 , 22, 437-44	7

835	Acetylcholine: a neurotransmitter for learning and memory?. 1995 , 21, 285-300	480
834	Cholinergic modulation of synaptic transmission in the rat visual cortex in vitro. 1995 , 35, 25-35	25
833	Pharmacologically induced changes in arousal: effects on behavioral and electrophysiologic measures of alertness and attention. 1995 , 95, 359-71	35
832	Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo. 1995 , 132, 1-15	22
831	Cholinergic binding sites in rat brain: analysis by age and cognitive status. 1995 , 16, 161-73	41
830	L-deprenyl and physostigmine for the treatment of Alzheimer's disease. 1995 , 58, 181-9	25
829	Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease. 1995 , 56, 883-90	22
828	Neuromodulation and cortical function: modeling the physiological basis of behavior. 1995 , 67, 1-27	433
827	The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. 1995 , 67, 165-99	257
826	Effects of theophylline and ipratropium on cognition in elderly patients with chronic obstructive pulmonary disease. 1996 , 76, 335-40	11
825	Quantitative Structure-Activity Relationships of Nicotinic Agonists. 1996 , 177-208	4
824	Inflammatory mechanisms and anti-inflammatory therapy in Alzheimer's disease. 1996 , 17, 669-71	31
823	Memory procedures, performance and processes in pigeons. 1996 , 3, 309-17	34
822	Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?. 1996 , 17, 155-60	43
821	Effect of Hachimi-jio-gan on scopolamine-induced memory impairment and on acetylcholine content in rat brain. 1996 , 50, 77-84	27
820	Immunohistochemical studies of localization and co-localization of glutamate, aspartate and GABA in the anterior thalamic nuclei, retrosplenial granular cortex, thalamic reticular nucleus and mammillary nuclei of the rat. 1996 , 12, 77-84	28
819	Cognition enhancers in age-related cognitive decline. 1996 , 8, 245-74	53
818	Serial pattern learning in senescent rats: a comparison of acquisition performance with young and hippocampal-lesioned rats. 1996 , 123, 137-49	2

817	Cholinergic therapy and Lewy body dementia. 1996 , 414-424		1
816	Cholinomimetic treatment of Alzheimer's disease. 1996 , 109, 299-309		6
815	Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 13541-6	11.5	282
814	Galanin receptor antagonist M40 blocks galanin-induced choice accuracy deficits on a delayed-nonmatching-to-position task.. 1996 , 110, 1025-1032		49
813	Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. 1996 , 706, 181-93		454
812	Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor. 1996 , 714, 87-94		20
811	Cognitive effects of scopolamine in dementia. 1996 , 103, 873-81		10
810	The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. 1996 , 123, 361-73		40
809	Age-related decline in central cholinergic function demonstrated with scopolamine. 1996 , 125, 50-6		49
808	Expression of m1-m4 muscarinic acetylcholine receptor immunoreactivity in septohippocampal neurons and other identified hippocampal afferents. 1996 , 375, 406-16		49
807	KEY PAPERS IN GERIATRIC PSYCHIATRY. SERIES EDITOR: ALISTAIR BURNS Correlation of Cholinergic Abnormalities with Senile Plaques and Mental Test Scores in Senile Dementia. E. Perry, B. Tomlinson, G. Blessed, K. Bergmann, P. Gibson and R. Perry, <i>British Medical Journal</i> (1978)2, 1457-59.. 1996 , 11, 765-771		2
806	Synthesis and enantioselectivity of the enantiomers of PG9 and SM21, new potent analgesic and cognition-enhancing drugs. 1996 , 8, 225-33		10
805	Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease. 1996 , 38, 278-289		31
804	Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. 1996 , 60, 276-82		46
803	The Current Status of the Calcium Hypothesis of Brain Aging and Alzheimer's Disease. Report of a workshop Heidelberg October 23-25, 1995. 1996 , 2, 1-20		
802	The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. 1996 , 109, 285-97		93
801	d-Cycloserine enhances implicit memory in Alzheimer patients. 1996 , 46, 420-4		128
800	A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. 1996 , 47, 1389-95		73

799	Effects of <i>Gastrodia elata</i> and its active constituents on scopolamine-induced amnesia in rats. <i>Planta Medica</i> , 1996 , 62, 317-21	3.1	58
798	Molecular neurobiology of Alzheimer's disease (syndrome?). 1997 , 5, 177-213		26
797	Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. 1997 , 154, 799-804		358
796	Basal forebrain amnesia. 1997 , 3, 405-415		5
795	Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. 1997 , 49, 153-61		47
794	1 Pharmacology of Alzheimer's Disease. 1997 , 34, 1-67		6
793	Age-related loss of calbindin from human basal forebrain cholinergic neurons. 1997 , 8, 2209-13		32
792	Analysis of galanin and the galanin antagonist M40 on delayed non-matching-to-position performance in rats lesioned with the cholinergic immunotoxin $\alpha\beta\text{G}$ -Saporin.. 1997 , 111, 552-563		35
791	Effect of long-term administration of berberine on scopolamine-induced amnesia in rats. 1997 , 74, 261-6		55
790	Chapter VII Chemical neuroanatomy of the primate insula cortex: Relationship to cytoarchitectonics, connectivity, function and neurodegeneration. 1997 , 377-454		7
789	Effects of increased cholinergic activity on naming in aphasia. 1997 , 350, 116-7		55
788	Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans. 1997 , 41, 50-7		11
787	Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. 1997 , 11, 206-28		200
786	Positron emission tomographic investigations of central muscarinic cholinergic receptors with three isomers of $[76\text{Br}]\text{BrQNP}$. 1997 , 24, 475-82		2
785	Life and death of neurons in the aging brain. 1997 , 278, 412-9		1083
784	A dissociation between perceptual explicit and implicit memory processes. 1997 , 35, 42-57		24
783	Zinc metabolism in the brain: relevance to human neurodegenerative disorders. 1997 , 4, 137-69		479
782	Inhibition of intermediate-term memory following passive avoidance training in neonate chicks by a presynaptic cholinergic blocker. 1997 , 67, 207-13		11

781	Cholinergic immunolesions by 192IgG-saporin--useful tool to simulate pathogenic aspects of Alzheimer's disease. 1997 , 15, 835-50	37
780	Cholinergic modulation, visual function and Alzheimer's dementia. 1997 , 37, 3559-71	84
779	Cholinergic activity and amyloid precursor protein metabolism. 1997 , 25, 50-69	105
778	Zinc and Alzheimer's disease: is there a direct link?. 1997 , 23, 219-36	135
777	Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. 1997 , 82, 195-202	59
776	Vinconate, a cognitive enhancer, and PI turnover-phospholipase C systems in the brain. 1997 , 83, 75-81	1
775	Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands. 1997 , 21, 69-102	182
774	Vesicular acetylcholine transporter density and Alzheimer's disease. 1997 , 18, 407-13	68
773	Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex. 1997 , 42, 59-70	41
772	Glutamate and aspartate immunoreactivity in the reciprocal projections between the anterior thalamic nuclei and the retrosplenial granular cortex in the rat. 1997 , 42, 309-21	22
771	Localization of M1 muscarinic receptors in rat brain using selective muscarinic toxin-1. 1997 , 44, 597-601	29
770	Gastrodin and p-hydroxybenzyl alcohol facilitate memory consolidation and retrieval, but not acquisition, on the passive avoidance task in rats. 1997 , 56, 45-54	104
769	Effect of Long-Term Administration of Berberine on Scopolamine-Induced Amnesia in Rats. 1997 , 74, 261-266	4
768	The effects of nerve growth factor on spatial recent memory in aged rats persist after discontinuation of treatment. 1997 , 17, 2543-50	53
767	Physostigmine reversal of scopolamine-induced hypofrontality. 1997 , 17, 220-8	39
766	Effects of delayed treatment with nebracetam on neurotransmitters in brain regions after microsphere embolism in rats. 1997 , 121, 477-84	4
765	Acetylcholine, aging, and Alzheimer's disease. 1997 , 56, 687-96	277
764	Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory and learning in human subjects: comparison with diazepam and implications for dementia. 1997 , 134, 95-106	114

763	SAR studies on the potent and selective muscarinic antagonist 2-ethylthio-2,2-diphenylacetic acid N,N-diethylaminoethyl ester. 1997 , 330, 122-8	4
762	EEG correlates of acute nicotinic and muscarinic cholinergic blockade: separate and combined administration of mecamylamine and scopolamine in normal human subjects. 1997 , 12, 573-582	10
761	WAL 2014 FU (talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease. 1997 , 40, 144-157	13
760	Imaging of cholinergic terminals using the radiotracer [18F](+)-4-fluorobenzyltrozamicol: in vitro binding studies and positron emission tomography studies in nonhuman primates. 1997 , 25, 368-80	43
759	Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins. 1998 , 12, 473-81	37
758	Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent. 1998 , 4, 247-259	7
757	The effect of hypothalamic peptide YY on hippocampal acetylcholine release in vivo: implications for limbic function in binge-eating behavior. 1998 , 805, 20-8	19
756	Scopolamine-induced impairment in concurrent fixed-interval responding in a radial maze task. 1998 , 59, 641-7	6
755	Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. 1998 , 60, 377-86	107
754	Cholinergic excitation induces activity-dependent electrophysiological and transcriptional responses in hippocampal slices. 1998 , 92, 329-35	9
753	Effects of NIK-247 and tacrine on muscarinic receptor subtypes in rats. 1998 , 30, 537-41	4
752	NIK-247 induces long-term potentiation of synaptic transmission in the CA1 region of rat hippocampal slices through M2 muscarinic receptors. 1998 , 31, 297-300	9
751	Drugs that increase intelligence?: Application for childhood cognitive impairment. 1998 , 4, 36-49	2
750	Effects of physostigmine on scopolamine-induced changes in quantitative electroencephalogram and cognitive performance. 1998 , 13, 199-210	17
749	Non-mnemonic cognitive function in the scopolamine model of Alzheimer's Disease. 1998 , 13, 439-449	21
748	m2 muscarinic acetylcholine receptor-immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer's disease: Relationship with cholinergic and galaninergic perikarya. 1998 , 392, 313-329	19
747	Inhibition of antagonist and agonist binding to the human brain muscarinic receptor by arachidonic acid. 1998 , 10, 209-17	15
746	Cognitive impairment in Parkinson's disease. 1998 , 5, 431-441	20

745	Scopolamine model of dementia: electroencephalogram findings and cognitive performance. 1998 , 28, 944-9	256
744	Sensitivity to cholinergic drug treatments of aged rats with variable degrees of spatial memory impairment. 1999 , 98, 53-66	42
743	EKG phosphatidylcholine combined with vitamin B12 improved memory impairment following lesioning of nucleus basalis in rats. 1998 , 62, 813-22	27
742	Effects of lesions of the Substantia Innominata/Ventral Pallidum, globus pallidus and medial septum on rat's performance in object-recognition and radial-maze tasks: physostigmine and amphetamine treatments. 1998 , 38, 251-63	44
741	Alzheimer's disease. Cholinergic therapy and beyond. 1998 , 6, S56-63	8
740	Individual differences in spatial memory and striatal ChAT activity among young and aged rats. 1998 , 70, 314-27	47
739	Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. 1998 , 349, 137-42	65
738	Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. 1998 , 51, S18-29; discussion S65-7	145
737	A non-invasive system for delivering neural growth factors across the blood-brain barrier: a review. 1998 , 9, 31-55	55
736	Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. 1998 , 50, 1222-30	273
735	Memory Changes during Normal Aging. 1998 , 247-287	8
734	Effects of Jen-San-Yaung-Jung-Tang on scopolamine-induced amnesia in rats. 1998 , 26, 117-25	2
733	Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 11465-70	11.5 234
732	Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor. 1998 , 9, 171-6	25
731	Neuropsychological Assessment of the Elderly. 1998 , 133-169	6
730	Neuropathology and memory dysfunction in neurodegenerative disease. 1998 , 36-86	2
729	Neurochemical aspects of memory dysfunction in neurodegenerative disease. 1998 , 87-99	
728	Prenatal dietary choline supplementation decreases the threshold for induction of long-term potentiation in young adult rats. 1998 , 79, 1790-6	143

727	Neuroactive Neurosteroids as Endogenous Effectors for the Sigma1 (σ ₁) Receptor: Pharmacological Evidence and Therapeutic Opportunities. 1999 , 81, 125-154	18
726	Should schizophrenia be treated as a neurocognitive disorder?. 1999 , 25, 309-19	323
725	The effects of scopolamine on changes in regional cerebral blood flow during classical conditioning of the human eyeblink response. 1999 , 39, 187-95	8
724	Synthesis and antagonistic activity at muscarinic receptor subtypes of some 2-carbonyl derivatives of diphenidol. 1999 , 7, 1837-44	6
723	Anandamides inhibit binding to the muscarinic acetylcholine receptor. 1999 , 13, 55-61	29
722	Amnesic effects of the anticholinergic drugs, trihexyphenidyl and biperiden: differences in binding properties to the brain muscarinic receptor. 1999 , 834, 6-12	21
721	Facilitation of memory performance by a novel muscarinic agonist in young and old rats. 1999 , 63, 663-7	15
720	Estradiol facilitates performance as working memory load increases. 1999 , 24, 161-73	254
719	Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. 1999 , 7, 297-307	571
718	Evidence that nerve growth factor influences recent memory through structural changes in septohippocampal cholinergic neurons. 1999 , 405, 491-507	50
717	Separate and combined effects of scopolamine and mecamylamine on human event-related brain potentials. 1999 , 14, 307-317	7
716	Behavioural problems associated with dementia: the role of newer antipsychotics. 1999 , 14, 41-54	68
715	The cholinergic hypothesis of Alzheimer's disease: a review of progress. 1999 , 66, 137-47	1373
714	Regulating and assessing risks of cholinesterase-inhibiting pesticides: divergent approaches and interpretations. 1999 , 2, 105-60	43
713	Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. 1999 , 8, 203-12	69
712	Cholinergic neurons of the nucleus basalis of Meynert receive cholinergic, catecholaminergic and GABAergic synapses: an electron microscopic investigation in the monkey. 1999 , 88, 241-55	40
711	Immunoelectron microscopic study of glutamate inputs from the retrosplenial granular cortex to identified thalamocortical projection neurons in the anterior thalamus of the rat. 1999 , 50, 63-76	10
710	Reappraising neurotransmitter-based strategies. 1999 , 9 Suppl 2, S53-9	10

709	Muscarinic receptor subtypes involved in hippocampal circuits. 1999 , 64, 501-9	83
708	The effects of nicotine on learning and memory: a neuropsychological assessment in young and senescent Fischer 344 rats. 1999 , 67, 421-31	36
707	Mutation screening of the CHRNA4 and CHRN2 nicotinic cholinergic receptor genes in Alzheimer's disease. 1999 , 10, 2919-22	10
706	Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities. 1999 , 81, 125-55	160
705	The cholinergic deficit in Alzheimer's disease: impact on cognition, behaviour and function. 2000 ,	
704	Threat perceptions and avoidance in recurrent dreams. 2000 , 23, 1017-1018	4
703	The ameliorating effects of the cognitive-enhancing Chinese herbs on scopolamine-induced amnesia in rats. 2000 , 14, 375-7	87
702	The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. 2000 , 176, 74-84	55
701	Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. 2000 , 31, 131-44	140
700	Cholinergic modulation of neocortical long-term potentiation in the awake, freely moving rat. 2000 , 881, 28-36	17
699	Age-Associated Memory Impairment. 2000 , 2, 73-80	6
698	The role of nicotinic and muscarinic acetylcholine receptors in attention. 2000 , 148, 243-50	85
697	How does the dreaming brain explain the dreaming mind?. 2000 , 23, 904-907	127
696	Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. 2000 , 130, 1629-32	62
695	Lucid dreaming: Evidence and methodology. 2000 , 23, 962-964	34
694	Sorting out additions to the understanding of cognition during sleep. 2000 , 23, 973-975	3
693	Koch's postulates confirm cholinergic modulation of REM sleep. 2000 , 23, 966-966	0
692	How and why the brain makes dreams: A report card on current research on dreaming. 2000 , 23, 914-916	3

691	Conceptual coordination bridges information processing and neurophysiology. 2000 , 23, 919-922	1
690	Heart simulation, dreams, and domain-specificity. 2000 , 23, 1004-1004	
689	Where is the forest? Where is the dream?. 2000 , 23, 943-945	4
688	Dreaming is not a non-conscious electrophysiologic state. 2000 , 23, 984-988	
687	Dreaming as an active construction of meaning. 2000 , 23, 907-908	1
686	Epandrels of the night? 2000 , 23, 966-967	1
685	Neural constraints on cognition in sleep. 2000 , 23, 994-995	1
684	Some myths are slow to die. 2000 , 23, 999-1000	1
683	Nielsen's concept of covert REM sleep is a path toward a more realistic view of sleep psychophysiology. 2000 , 23, 983-984	2
682	Iterative processing of information during sleep may improve consolidation. 2000 , 23, 919-919	1
681	Evolutionary psychology can ill afford adaptationist and mentalist credulity. 2000 , 23, 1013-1014	1
680	Novel concepts of sleep-wakefulness and neuronal information coding. 2000 , 23, 968-971	
679	Toward a new neuropsychological isomorphism. 2000 , 23, 980-981	1
678	REM and NREM mentation: Nielsen's model once again supports the supremacy of REM. 2000 , 23, 913-914	1
677	REM sleep: Desperately seeking isomorphism. 2000 , 23, 931-934	4
676	The mechanism of the REM state is more than a sum of its parts. 2000 , 23, 1008-1009	
675	The pharmacology of threatening dreams. 2000 , 23, 1016-1017	2
674	Forebrain mechanisms of dreaming are activated from a variety of sources. 2000 , 23, 1035-1040	2

673	State-dependent modulation of cognitive function. 2000 , 23, 945-946	
672	A more general evolutionary hypothesis about dream function. 2000 , 23, 972-973	5
671	The divorce of REM sleep and dreaming. 2000 , 23, 922-924	2
670	The illusory function of dreams: Another example of cognitive bias. 2000 , 23, 971-972	4
669	Dream research: Integration of physiological and psychological models. 2000 , 23, 1001-1003	15
668	New multiplicities of dreaming and REMing. 2000 , 23, 953-955	4
667	A new approach for explaining dreaming and REM sleep mechanisms. 2000 , 23, 558-559	
666	The prevalence of typical dream themes challenges the specificity of the threat simulation theory. 2000 , 23, 940-941	5
665	The waking-to-dreaming continuum and the effects of emotion. 2000 , 23, 947-950	8
664	Nightmares: Friend or foe?. 2000 , 23, 965-965	3
663	Search activity: A key to resolving contradictions in sleep/dream investigation. 2000 , 23, 996-999	1
662	Needed: A new theory. 2000 , 23, 928-930	3
661	Insights from functional neuroimaging studies of behavioral state regulation in healthy and depressed subjects. 2000 , 23, 979-980	
660	The contents of consciousness during sleep: Some theoretical problems. 2000 , 23, 995-996	1
659	Dreams and sleep: Are new schemas revealing?. 2000 , 23, 976-976	0
658	Shedding old assumptions and consolidating what we know: Toward an attention-based model of dreaming. 2000 , 23, 924-928	9
657	Inclusive versus exclusive approaches to sleep and dream research. 2000 , 23, 1011-1013	13
656	Reflexive and orienting properties of REM sleep dreaming and eye movements. 2000 , 23, 950-950	1

655	The interpretation of physiology. 2000 , 23, 955-956	5
654	The ghost of Sigmund Freud haunts Mark Solms's dream theory. 2000 , 23, 951-952	6
653	Papez dreams: Mechanism and phenomenology of dreaming. 2000 , 23, 961-962	
652	Time course of dreaming and sleep organization. 2000 , 23, 1000-1000	1
651	REM sleep = dreaming: The never-ending story. 2000 , 23, 916-917	1
650	“The dream of reason creates monsters” . . . especially when we neglect the role of emotions in REM-states. 2000 , 23, 988-990	4
649	Mental states during dreaming and daydreaming: Some methodological loopholes. 2000 , 23, 917-918	14
648	One machinery, multiple cognitive states: The value of the AIM model. 2000 , 23, 993-994	
647	The dramaturgy of dreams in Pleistocene minds and our own. 2000 , 23, 946-947	
646	Continued vitality of the Freudian theory of dreaming. 2000 , 23, 1004-1006	2
645	Sleep, not REM sleep, is the royal road to dreams. 2000 , 23, 911-912	2
644	Play, dreams, and simulation. 2000 , 23, 918-919	7
643	Each distinct type of mental state is supported by specific brain functions. 2000 , 23, 941-943	6
642	Dreaming as play. 2000 , 23, 953-953	11
641	Dreaming has content and meaning not just form. 2000 , 23, 959-961	5
640	All brain work [including recall] is state-dependent. 2000 , 23, 964-965	2
639	Dream production is not chaotic. 2000 , 23, 967-968	2
638	Sleep can be related to memory, even if REM sleep is not. 2000 , 23, 971-971	5

637	Metaphoric threat is more real than real threat. 2000 , 23, 992-993	11
636	Effects of estrogen on basal forebrain cholinergic neurons and cognition: implications for brain aging and dementia in women. 2000 , 183-222	2
635	Mesolimbic dopamine and the neuropsychology of dreaming: Some caution and reconsiderations. 2000 , 23, 930-931	2
634	Critical brain characteristics to consider in developing dream and memory theories. 2000 , 23, 977-978	
633	Sleep, dreaming, and brain activation. 2000 , 23, 939-940	1
632	Neuronal basis of dreaming and mentation during slow-wave (non-REM) sleep. 2000 , 23, 1009-1011	10
631	Dreams have meaning but no function. 2000 , 23, 910-911	4
630	Expanding Nielsen's covert REM model, questioning Solms's approach to dreaming and REM sleep, and reinterpreting the Vertes & Eastman view of REM sleep and memory. 2000 , 23, 981-983	4
629	The problem of dreaming in NREM sleep continues to challenge reductionist (two generator) models of dream generation. 2000 , 23, 956-958	2
628	REM sleep is not committed to memory. 2000 , 23, 1057-1063	11
627	Geriatric Psychopharmacology: Why Does Age Matter?. 2000 , 7, 311-333	21
626	Synaptic alterations in the vestibulocerebellar system in Alzheimer's disease--a Golgi and electron microscope study. 2000 , 120, 247-50	39
625	Galantamine: additional benefits to patients with Alzheimer's disease. 2000 , 11 Suppl 1, 19-27	25
624	Post-traumatic nightmares as a dysfunctional state. 2000 , 23, 978-979	7
623	Dream science 2000: A response to commentaries on Dreaming and the brain. 2000 , 23, 1019-1035	9
622	The case against memory consolidation in REM sleep: Balderdash!. 2000 , 23, 934-936	4
621	Dreaming is not an adaptation. 2000 , 23, 936-939	12
620	Internally-generated activity, non-episodic memory, and emotional salience in sleep. 2000 , 23, 908-909	3

619	REM sleep deprivation: The wrong paradigm leading to wrong conclusions. 2000 , 23, 912-913	29
618	Did ancestral humans dream for their lives?. 2000 , 23, 1063-1082	18
617	Neurotransmitter mechanisms of dreaming: Implication of modulatory systems based on dream intensity. 2000 , 23, 990-992	36
616	Donepezil therapy in clinical practice: a randomized crossover study. <i>Archives of Neurology</i> , 2000 , 57, 94-9	145
615	Covert REM sleep effects on REM mentation: Further methodological considerations and supporting evidence. 2000 , 23, 1040-1057	25
614	On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. 2000 , 163, 495-529	567
613	Cyto- and chemoarchitecture of basal forebrain cholinergic neurons in the common marmoset (<i>Callithrix jacchus</i>). 2000 , 165, 306-26	15
612	Scopolamine reduces sensitivity to auditory gaps in the rat, suggesting a cholinergic contribution to temporal acuity. 2000 , 145, 169-76	32
611	Effect of Indian <i>Hypericum perforatum</i> Linn on animal models of cognitive dysfunction. 2000 , 72, 119-28	41
610	Alteration of expression levels of neuronal nitric oxide synthase and haem oxygenase-2 messenger RNA in the hippocampi and cortices of young adult and aged cognitively unimpaired and impaired Long-Evans rats. 2000 , 100, 769-75	39
609	Immunohistochemical and neurochemical correlates of learning deficits in aged rats. 2000 , 96, 275-89	100
608	Localization of amino acids, neuropeptides and cholinergic markers in neurons of the septum-diagonal band complex projecting to the retrosplenial granular cortex of the rat. 2000 , 52, 499-510	23
607	Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. 2000 , 115, 235-49	148
606	Can the cognitive enhancing effects of ginkgo biloba be explained by its pharmacology?. 2000 , 55, 491-3	38
605	Evaluation of two rodent delayed-response memory tasks: a method with retractable levers versus a method with closing doors. 2000 , 70, 233-41	3
604	Metrifonate. 2000 , 13, 443-467	4
603	Therapeutic opportunities for muscarinic receptors in the central nervous system. 2000 , 43, 4333-53	197
602	Nicotinic treatment of Alzheimer's disease. 2001 , 49, 268-78	109

601	Cholinergic Treatments of Alzheimer's Disease. 2001 , 475-486	3
600	Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. 2001 , 41, 51-60	42
599	References. 2001 , 295-334	
598	Growth Hormone, Insulin-like Growth Factor- 1, and the Aging Brain. 2001 , 907-928	1
597	Alzheimer disease therapeutics. 2001 , 60, 923-8	33
596	Role of serotonin in the behavioral and psychological symptoms of dementia. 2001 , 13, 5-21	85
595	Improved incidental memory with nicotine after semantic processing, but not after phonological processing. 2001 , 153, 258-63	43
594	The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. 2001 , 16, 345-351	72
593	Cholinergic modulation of cognitive function in healthy subjects: acute effects of donepezil, a cholinesterase inhibitor. 2001 , 16, 481-483	11
592	Peripheral blood lymphocytes muscarinic cholinergic receptor subtypes in Alzheimer's disease: a marker of cholinergic dysfunction?. 2001 , 121, 126-31	19
591	Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?. 2001 , 122, 2025-40	81
590	The acoustic cortex in frontal dementia. 2001 , 121, 289-92	10
589	The neurology of memory. 2001 , 22, 95-105	1
588	Donepezil in the treatment of patients with Alzheimer's disease. 2001 , 1, 11-9	6
587	Drug treatment of Alzheimer's disease. 2002 , 12, 165-173	
586	Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance. 2002 , 35, 190-4	17
585	Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. 2002 , 35, 6-11	26
584	Gonadal Steroids, Learning, and Memory. 2002 , 265-327	29

583	Evidence concerning how neurons of the perirhinal cortex may effect familiarity discrimination. 2002 , 357, 1083-95	72
582	Effects of T-82, a new quinoline derivative, on cholinesterase activity and extracellular acetylcholine concentration in rat brain. 2002 , 88, 206-12	22
581	The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. 2002 , 24, 697-713	24
580	3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 Å resolution: kinetic and molecular dynamic correlates. 2002 , 41, 2970-81	112
579	Muscarinic M1 receptor agonists and M2 receptor antagonists as therapeutic targets in Alzheimer's disease. 2002 , 12, 863-870	17
578	No spatial working memory deficit in beta-amyloid-exposed rats. A longitudinal study. 2002 , 26, 955-70	13
577	Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. 2002 , 68, 209-45	527
576	Biological Research on Dementias. 287-322	
575	. 2002 ,	6
574	Impact of Hormone Replacement Therapy on stroke, and dementia due to Alzheimer's disease on menopausal women. 2002 , 11, 246	
573	The acute nootropic effects of Ginkgo biloba in healthy older human subjects: a preliminary investigation. 2002 , 17, 45-9	25
572	Role of amyloid β peptides in the regulation of central cholinergic function and its relevance to Alzheimer's disease pathology. 2002 , 56, 248-263	8
571	Talsaclidine (WAL 2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease. 2002 , 56, 321-334	16
570	Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?. 2002 , 56, 369-379	2
569	The effect of scopolamine in older rabbits tested in the 750 ms delay eyeblink classical conditioning procedure. 2002 , 37, 103-13	4
568	Use of anticholinergic medications by older adults with dementia. 2002 , 50, 836-42	113
567	PET imaging of brain acetylcholinesterase using [¹¹ C]CP-126,998, a brain selective enzyme inhibitor. 2002 , 45, 1-9	30
566	Memory deficits in Alzheimer's disease: the encoding hypothesis and cholinergic function. 2002 , 9, 426-37	48

- 565 Verbal fluency facilitated by the cholinergic blocker, scopolamine. **2002**, 17, 51-9 12
- 564 Have cholinergic therapies reached their clinical boundary in Alzheimer's disease?. **2003**, 18, S7-S13 99
- 563 Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. **2003**, 49, 150-6 55
- 562 Anti-amnesic effect of dimemorfan in mice. **2003**, 138, 941-9 22
- 561 Age-related sex differences in spatial learning and basal forebrain cholinergic neurons in F344 rats. **2003**, 80, 27-36 55
- 560 Age-related deficits as working memory load increases: relationships with growth factors. **2003**, 24, 37-48 133
- 559 Intraseptal infusion of oxotremorine impairs memory in a delayed-non-match-to-sample radial maze task. **2003**, 121, 259-67 22
- 558 Zinc takes the center stage: its paradoxical role in Alzheimer's disease. **2003**, 41, 44-56 191
- 557 Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. **2003**, 139, 47-57 132
- 556 Behavioral comparison of 4 and 6 month-old Ts65Dn mice: age-related impairments in working and reference memory. **2003**, 138, 121-31 93
- 555 Cholinergic neurotransmission is essential for perirhinal cortical plasticity and recognition memory. **2003**, 38, 987-96 183
- 554 Social transmission of food preference in mice: Methodology and application to galanin-overexpressing transgenic mice.. **2003**, 117, 21-31 94
- 553 Preventing and treating Alzheimer's disease: strategies and prospects. **2003**, 3, 565-9 5
- 552 Modulation of mood and cognitive performance following acute administration of single doses of *Melissa officinalis* (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. **2003**, 28, 1871-81 132
- 551 Effects of scopolamine on matching to sample paradigm and related tests in human subjects. **2003**, 48, 87-94 29
- 550 The cholinergic deficiency syndrome and its therapeutic implications. **2003**, 49, 55-60 51
- 549 Tolterodine and memory: dry but forgetful. *Archives of Neurology*, **2003**, 60, 771-3 92
- 548 Regulation of attention and response to therapy in dementia by butyrylcholinesterase. **2003**, 13, 231-9 78

547	Muscarinic receptors in schizophrenia: is there a role for synaptic plasticity?. 2004 , 59, 93-109	
546	Neuropharmacology of verbal perseveration. 2004 , 25, 309-21	29
545	Donepezil: a clinical review of current and emerging indications. 2004 , 5, 161-80	32
544	Septohippocampal acetylcholine: involved in but not necessary for learning and memory?. 2004 , 11, 9-20	152
543	Neuropsychological test performance in healthy volunteers before and after donepezil administration. 2004 , 18, 102-8	47
542	Effect of treatment with the cholinesterase inhibitor rivastigmine on vesicular acetylcholine transporter and choline acetyltransferase in rat brain. 2004 , 26, 363-73	23
541	The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. 2004 , 11, 43-9	334
540	Amyloid beta peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer's disease pathology. 2004 , 145, 261-74	27
539	Cholinergic modulation of visual attention and working memory: dissociable effects of basal forebrain 192-IgG-saporin lesions and intraprefrontal infusions of scopolamine. 2004 , 11, 78-86	107
538	Endogenous acetylcholine lowers the threshold for long-term potentiation induction in the CA1 area through muscarinic receptor activation: in vivo study. 2004 , 20, 1267-75	130
537	The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. 2004 , 28, 497-505	388
536	Dose-specific effects of scopolamine on canine cognition: impairment of visuospatial memory, but not visuospatial discrimination. 2004 , 175, 92-8	34
535	Effects of nicotine and mecamylamine on cognition in rhesus monkeys. 2004 , 175, 225-40	42
534	The cholinergic innervation of the human cerebral cortex. 2004 , 145, 67-78	136
533	High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. 2004 , 145, 207-31	378
532	S 18986, a positive modulator of AMPA receptors with cognition-enhancing properties, increases ACh release in the hippocampus of young and aged rat. 2004 , 361, 120-3	28
531	Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. 2004 , 25, 873-84	60
530	Effect of Polygala tenuifolia root on behavioral disorders by lesioning nucleus basalis magnocellularis in rat. 2004 , 95, 47-55	31

529	Neurochemical imaging of dementias. 2004 , 34, 70-82	16
528	EEG dynamics in patients with Alzheimer's disease. 2004 , 115, 1490-505	850
527	Donepezil in the treatment of dementia. 2005 , 1, 7-17	2
526	Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study. 2005 , 25, 159-65	44
525	The interplay of neurotransmitters in Alzheimer's disease. 2005 , 10, 6-9	141
524	De biologie van het geheugen. 2005 , 9, 132-136	
523	Selective cholinergic immunolesioning affects synaptic plasticity in developing visual cortex. 2005 , 21, 1807-14	26
522	Absence of long-term behavioral effects after sub-chronic administration of low doses of methamidophos in male and female rats. 2005 , 27, 279-97	16
521	Cholinergic dysfunction in vascular dementia. 2005 , 7, 18-26	37
520	Uncommon causes of dementia: an historical account. 2005 , 17 Suppl 1, S3-15	2
519	Acetylcholinesterase as a window onto stress responses. 2005 , 15, 585-608	3
518	Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. 2005 , 76, 315-9	121
517	Pharmacological modulation of prefrontal cortical activity during a working memory task in young and older humans: a PET study with physostigmine. 2005 , 162, 2061-70	37
516	Cholinergic inhibition of neocortical pyramidal neurons. 2005 , 25, 10308-20	132
515	Commentary on "Diagnosis of Alzheimer's disease: two decades of progress." Alzheimer's disease: years of progress, and an army of researchers recruited; AD remains an elusive adversary. 2005 , 1, 109-11	1
514	Donepezil: a review. 2005 , 1, 527-36	61
513	Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. 2005 , 380, 127-32	89
512	Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. 2005 , 27, 144-53	120

511	Further analysis of the effects of immunotoxic lesions of the basal nucleus of Meynert reveals substantial impairment on visual discrimination learning in monkeys. 2005 , 65, 433-42	17
510	Effects of scopolamine challenge on regional cerebral blood volume. A pharmacological model to validate the use of contrast enhanced magnetic resonance imaging to assess cerebral blood volume in a canine model of aging. 2005 , 29, 399-406	13
509	Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. 2005 , 29, 411-22	95
508	The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs. 2005 , 29, 489-98	61
507	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. 2006 , 49, 2174-85	64
506	Alzheimer: 100 Years and Beyond. 2006 ,	5
505	Complexes of alkylene-linked tacrine dimers with <i>Torpedo californica</i> acetylcholinesterase: Binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge. 2006 , 49, 5491-500	170
504	Ginkgo biloba normalizes stress- and corticosterone-induced impairment of recall in rats. 2006 , 53, 123-8	41
503	Nerve growth factor in treatment and pathogenesis of Alzheimer's disease. 2006 , 80, 114-28	75
502	Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys. 2006 , 51, 238-50	57
501	Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats. 2006 , 142, 505-14	143
500	CIMT as a behavioral engine in research on physiological adjuvants to neurorehabilitation: The challenge of merging animal and human research. 2006 , 21, 107-130	12
499	Estrogen therapy after menopause: role in normal cognition and Alzheimer's disease. 2006 , 2, 955-966	1
498	Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. 2006 , 9, 175-89	114
497	Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. 2006 , 34, 339-47	36
496	Functional magnetic resonance imaging of cholinergic modulation in mild cognitive impairment. 2006 , 19, 299-306	17
495	Cytoskeletal transport in the aging brain: focus on the cholinergic system. 2006 , 17, 581-618	17
494	The determination of huperzine A in European Lycopodiaceae species by HPLC-UV-MS. 2006 , 17, 332-6	19

493	Age and APOE-epsilon4 genotype influence the effect of physostigmine infusion on the in-vivo distribution volume of the muscarinic-2-receptor dependent tracer [18F]FP-TZTP. 2006 , 60, 86-92	16
492	Aging decreases the sensitivity of rat cortical synaptosomes to calcium ionophore-induced acetylcholine release. 1986 , 47, 1244-6	64
491	Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP. 2006 , 113, 1225-41	14
490	The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. 2006 , 113, 1625-44	392
489	Temporal and region-dependent changes in muscarinic M4 receptors in the hippocampus and entorhinal cortex of adrenalectomized rats. 2006 , 173, 309-17	5
488	The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. 2006 , 54, 99-105	122
487	Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. 2006 , 127, 173-9	29
486	Animal models of cognitive dysfunction. 2006 , 127, 100-8	13
485	Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women. 2006 , 31, 2065-78	70
484	Alzheimer's centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects. 2006 , 129, 2811-22	145
483	Sympathetic sprouting drives hippocampal cholinergic reinnervation that prevents loss of a muscarinic receptor-dependent long-term depression at CA3-CA1 synapses. 2006 , 26, 3745-56	60
482	Donepezil for Alzheimer's disease. 2007 , 7, 1243-9	25
481	Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs. 2007 , 21, 272-82	26
480	Donepezil in the treatment of severe Alzheimer's disease. 2007 , 3, 419-435	
479	Anti-dementia drugs and hippocampal-dependent memory in rodents. 2007 , 18, 347-63	59
478	Characteristics of object location memory in mice: Behavioral and pharmacological studies. 2007 , 90, 116-24	113
477	Central Cholinergic Nervous System and Its Correlates. 2007 , 411-596	
476	Effects of luteolin on learning acquisition in rats: involvement of the central cholinergic system. 2007 , 80, 1692-8	40

475	Links Between Amyloid and Tau Biology in Alzheimer's Disease and Their Cholinergic Aspects. 2007 , 597-656	2
474	Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?. 2007 , 24, 881-90	23
473	Donepezil: an update. 2007 , 8, 1011-23	132
472	Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. 2007 , 177, 766-70	13
471	Drug Effects on Learning and Memory. 2007 , 877-942	1
470	[Delirium: screening, assessment and diagnosis]. 2007 , 20, 191-204	11
469	Muscarinic receptor dependent long-term depression in rat visual cortex is PKC independent but requires ERK1/2 activation and protein synthesis. 2007 , 98, 1862-70	32
468	Anticholinesterase activity of plastoquinones from <i>Sargassum sagamianum</i> : lead compounds for Alzheimer's disease therapy. 2007 , 21, 423-6	70
467	Idebenone. 2007 , 5, 217-235	1
466	The application of positron-emitting molecular imaging tracers in Alzheimer's disease. 2007 , 9, 204-16	22
465	Neuromodulation by glutamate and acetylcholine can change circuit dynamics by regulating the relative influence of afferent input and excitatory feedback. 2007 , 36, 184-200	121
464	The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates. 2008 , 199, 481-94	46
463	Memory and the brain: beyond intracranial phrenology. 2008 , 8, 269-73	
462	The effects of anticholinergic drugs on attention span and short-term memory skills in children. 2008 , 27, 315-8	34
461	Neurochemical and Behavioural Effects of Chronic Aldicarb Administration in Rats. 2008 , 89, 249-254	1
460	An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. 2008 , 4, 42-50	130
459	Hormesis and medicine. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 594-617	3.8 169
458	Enhancing the mind? Memory medicine, dementia, and the aging brain. 2008 , 22, 348-355	36

457	Alzheimer's disease drugs: an application of the hormetic dose-response model. 2008 , 38, 419-51	57
456	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. 2008 , 51, 6400-9	24
455	Cholinergic modulation of hippocampal CA1 basal-dendritic long-term potentiation. 2008 , 90, 382-8	44
454	Neurochemical effects following AF64A injection into the basal nuclei of rats. 1987 , 41, 755-62	
453	Cholinesterase inhibitors for delirium: what is the evidence?. 2008 , 20, 209-18	3
452	Synthesis of Cycloalkanoindoles, the Carba Analogs of Physostigmine. 2008 , 75, 43	10
451	Effects of donepezil on verbal memory after semantic processing in healthy older adults. 2008 , 21, 57-64	28
450	Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. <i>Clinical Interventions in Aging</i> , 2009 , 1	4 1
449	Glyconutrients and perception, cognition, and memory. 2009 , 108, 259-70	5
448	A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. 2009 , 76, 356-68	96
447	Neurotransmitter precursors: from animal experiments to human applications. 1986 , 44 Suppl, 193-204	4
446	Pharmacodynamic and early clinical studies with velnacrine. 1993 , 149, 26-8	18
445	Effect of nicotine on passive avoidance behaviour and motoric activity in mice. 1985 , 56, 337-41	34
444	Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. 2009 , 202, 15-36	26
443	Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. 2009 , 202, 53-65	72
442	Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies. 2009 , 207, 201-12	9
441	JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. 2009 , 56, 1131-7	45
440	The septo-hippocampal system, learning and recovery of function. 2009 , 33, 791-805	45

439	Proton magnetic resonance spectroscopy and cognition in patients with spastin mutations. 2009 , 277, 124-9	13
438	Errorless practice as a possible adjuvant to donepezil in Alzheimer's disease. 2009 , 15, 311-22	25
437	Syntheses and Uses of Isotopically Labelled Compounds Containing C?C, C?O or C?N Groups. 2009 ,	
436	Pharmacological Overview and Future Perspectives of Cholinergic Therapy in Alzheimers Disease. 2009 , 4, 65-72	1
435	Effects of aging and divided attention on memory for items and their contexts. 2010 , 25, 968-79	48
434	Basal forebrain integrity and cognitive memory profile in healthy aging. 2010 , 1308, 124-36	27
433	Cholinesterase inhibitors and memory. 2010 , 187, 403-8	92
432	The importance of being choline. 2010 , 110, 1162-5	12
431	The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. 2010 , 34, 1307-50	452
430	Design, synthesis and evaluation of carbamate-modified (-)-N(1)-phenethylnorphysostigmine derivatives as selective butyrylcholinesterase inhibitors. 2010 , 20, 1721-3	15
429	Neuroscientists as cartographers: mapping the crossroads of gonadal hormones, memory and age using animal models. 2010 , 15, 6050-105	33
428	The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects. 2010 , 24, 1671-9	29
427	A novel cognitive enhancer, ZSET1446/ST101, promotes hippocampal neurogenesis and ameliorates depressive behavior in olfactory bulbectomized mice. 2010 , 333, 43-50	40
426	[Delirium or behavioral and psychological symptoms of dementia in the elderly patient: diagnosis and treatment]. 2010 , 99, 1079-88	
425	Estrogen therapy and cognition: a review of the cholinergic hypothesis. 2010 , 31, 224-53	153
424	Hyoscyamus niger in der homöopathischen Therapie von Patienten mit Demenz. 2010 , 255, 6-11	
423	Carbachol-induced long-term synaptic depression is enhanced during senescence at hippocampal CA3-CA1 synapses. 2010 , 104, 607-16	15
422	Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. 2010 , 6, 1345-54	52

421	Asparagus recemosus enhances memory and protects against amnesia in rodent models. 2010 , 74, 1-9	50
420	NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. 2010 , 210, 221-8	23
419	Sympathetic sprouting in visual cortex stimulated by cholinergic denervation rescues expression of two forms of long-term depression at layer 2/3 synapses. 2010 , 168, 591-604	3
418	DRUG FOCUS: S 18986: A positive allosteric modulator of AMPA-type glutamate receptors pharmacological profile of a novel cognitive enhancer. 2010 , 16, e193-212	23
417	Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. 2011 , 10, 404-12	63
416	The history of the cholinergic hypothesis. 2011 , 221, 334-40	254
415	The cholinergic system and spatial learning. 2011 , 221, 389-411	180
414	The cholinergic system and hippocampal plasticity. 2011 , 221, 505-14	159
413	Acetylcholine and memory: a long, complex and chaotic but still living relationship. 2011 , 221, 424-9	118
412	The effect of pain on cognitive function: a review of clinical and preclinical research. 2011 , 93, 385-404	602
411	The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. 2011 , 25, 120-6	40
410	Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. 2011 , 26, 143-55	24
409	The prominent role of stimulus processing: cholinergic function and dysfunction in cognition. 2011 , 24, 364-70	35
408	Citidine-5-diphosphocholine Ameliorates the Impairment of Spatial Memory Induced by Scopolamine. 2011 , 57, 432-435	2
407	Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 886-98	3.8 33
406	Effects of maternal malnutrition and postnatal nutritional rehabilitation on brain fatty acids, learning, and memory. 2011 , 69, 132-44	50
405	Aged dogs demonstrate both increased sensitivity to scopolamine impairment and decreased muscarinic receptor density. 2011 , 98, 203-9	19
404	The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. 2011 , 99, 254-61	132

403	GPR30 is positioned to mediate estrogen effects on basal forebrain cholinergic neurons and cognitive performance. 2011 , 1379, 53-60		79
402	Galantamine: an update. 2011 , 1, 227-234		1
401	Cholinergic imbalance in the multiple sclerosis hippocampus. 2011 , 122, 313-22		55
400	Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. 2011 , 35, 1397-409		296
399	Kasuistik interaktiv: Bewusstlos nach Koloskopie [Ein neurologischer Notfall?]. 2011 , 27, 108-113		
398	Cognitive-enhancing effect of quercetin in a rat model of Parkinson's disease induced by 6-hydroxydopamine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012 , 2012, 823206	2-3	76
397	Cognitive-enhancing activity of thymol and carvacrol in two rat models of dementia. 2012 , 23, 241-9		66
396	Organophosphate-induced brain damage: mechanisms, neuropsychiatric and neurological consequences, and potential therapeutic strategies. 2012 , 33, 391-400		143
395	Reversal of scopolamine-induced spatial and recognition memory deficits in mice by novel multifunctional dimers bis-cognitins. 2012 , 1470, 59-68		24
394	The art of building multifunctional metal-binding agents from basic molecular scaffolds for the potential application in neurodegenerative diseases. 2012 , 256, 2308-2332		124
393	Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. 2012 , 10, 127		37
392	Y-Maze memory task in zebrafish (<i>Danio rerio</i>): the role of glutamatergic and cholinergic systems on the acquisition and consolidation periods. 2012 , 98, 321-8		103
391	Glycerophosphocholine enhances growth hormone secretion and fat oxidation in young adults. 2012 , 28, 1122-6		27
390	New insights into huperzine A for the treatment of Alzheimer's disease. 2012 , 33, 1170-5		46
389	Brainstem Cholinergic Systems. 2012 , 456-470		1
388	Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease. 2012 , 340, 595-603		52
387	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. 2012 , 135, 2470-7		53
386	Effect of fatty acids on the transdermal delivery of donepezil: in vitro and in vivo evaluation. 2012 , 422, 83-90		62

- 385 Untangling the role of tau in Alzheimer's disease: A unifying hypothesis. **2013**, 4, 8
- 384 Protective effect of *Cnestis ferruginea* and its active constituent on scopolamine-induced memory impairment in mice: a behavioral and biochemical study. **2013**, 51, 825-35 30
- 383 Memory consolidation [Mechanisms and opportunities for enhancement. **2013**, 4, 1
- 382 Concentrations of platelet α -adrenoceptors, lymphocyte muscarinic receptors, and blood monoamines in dogs (*Canis familiaris*) affected by canine cognitive dysfunction syndrome. **2013**, 8, 146-153 2
- 381 Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or A β in mice novel object and object location recognition tasks. **2013**, 70, 261-7 37
- 380 PP2A ligand ITH12246 protects against memory impairment and focal cerebral ischemia in mice. **2013**, 4, 1267-77 16
- 379 Effect of cholinesterase inhibitors on attention. **2013**, 203, 361-4 24
- 378 Role of cholinergic-muscarinic receptors in visual discrimination performance of rats: importance of stimulus load. **2013**, 238, 23-9 3
- 377 Handbook on the Neuropsychology of Aging and Dementia. **2013**, 7
- 376 Selective immunotoxic lesions of basal forebrain cholinergic cells: effects on learning and memory in rats. **2013**, 127, 619-27 15
- 375 Alzheimer disease pharmacologic treatment and treatment research. **2013**, 19, 339-57 20
- 374 Effects of dietary sialic acid in n-3 fatty acid-deficient dams during pregnancy and lactation on the learning abilities of their pups after weaning. **2013**, 59, 136-43 9
- 373 Effect of cholinergic signaling on neuronal cell bioenergetics. **2013**, 33, 1135-46 5
- 372 Soyasaponin I improved neuroprotection and regeneration in memory deficient model rats. **2013**, 8, e81556 13
- 371 Anticholinesterase, antioxidant, and neuroprotective effects of *Tripleurospermum disciforme* and *Dracocephalum multicaule*. **2014**, 5, 162-6 11
- 370 Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives. **2014**, 3-39 2
- 369 Presynaptic muscarinic receptors reduce synaptic depression and facilitate its recovery at hippocampal GABAergic synapses. **2014**, 24, 1818-31 7
- 368 A prospective test of the late effects of potentially antineuroplastic drugs in a stroke rehabilitation study. **2014**, 9, 449-56 10

367	Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. 2014 , 275, 251-83	437
366	Oral zinc reduces amyloid burden in Tg2576 mice. 2014 , 41, 179-92	22
365	Lessons Learned from Major Clinical Trials Conducted Over the Past Decades. 2014 , 77-97	2
364	An acetylcholinesterase inhibitor, eserine, induces long-term depression at CA3-CA1 synapses in the hippocampus of adult rats. 2014 , 112, 2388-97	16
363	Improving Effect of Atomoxetine and Reboxetine on Memory in Passive Avoidance Task. 2014 , 24, 211-219	1
362	Synaptosomal acetylcholinesterase activity variation pattern in the presence of electromagnetic fields. 2014 , 65, 8-15	7
361	Learning to remember: cognitive training-induced attenuation of age-related memory decline depends on sex and cognitive demand, and can transfer to untrained cognitive domains. 2014 , 35, 2791-2802	16
360	Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. 2014 , 35, 338-48	100
359	Potential pharmacological strategies for the improved treatment of organophosphate-induced neurotoxicity. 2014 , 92, 893-911	26
358	In vitro and ex-vivo cellular antioxidant protection and cognitive enhancing effects of an extract of Polygonum minus Huds (Lineminus) demonstrated in a Barnes Maze animal model for memory and learning. 2014 , 14, 161	18
357	Type 2 Diabetes and Inammation. 2014 , 153-160	
356	How Anticholinergic Drugs Might Promote Alzheimer's Disease: More Amyloid- β and Less Phosphatidylcholine. 2015 , 46, 983-7	11
355	Treatment of Alzheimer's Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions. 2015 , 47, 149-56	39
354	The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease. 2016 , 13, 53-67	43
353	Comparative Effect of Lisinopril and Fosinopril in Mitigating Learning and Memory Deficit in Scopolamine-Induced Amnesic Rats. 2015 , 2015, 521718	11
352	Protective Effect of Alpha Lipoic Acid against Phenytoin Induced Behavioral Abnormalities in Rats. 2015 , 06,	
351	Role of adult hippocampal neurogenesis in cognition in physiology and disease: pharmacological targets and biomarkers. 2015 , 228, 99-155	30
350	Important poisonous plants in tibetan ethnomedicine. 2015 , 7, 138-55	26

349	Restricted sedation and absence of cognitive impairments after administration of intranasal scopolamine. 2015 , 29, 1231-5	5
348	Multifunctional activity of polyphenolic compounds associated with a potential for Alzheimer's disease therapy from <i>Ecklonia cava</i> . 2015 , 29, 549-53	34
347	Behavioral-Cognitive Targets for Cholinergic Enhancement. 2015 , 4, 22-26	19
346	Scopolamine provocation-based pharmacological MRI model for testing procognitive agents. 2015 , 29, 447-55	6
345	Alzheimer's Disease Today. 2015 , 1-11	
344	Biperiden selectively induces memory impairment in healthy volunteers: no interaction with citalopram. 2015 , 232, 1887-97	20
343	Protection against brain tissues oxidative damage as a possible mechanism for the beneficial effects of <i>Rosa damascena</i> hydroalcoholic extract on scopolamine induced memory impairment in rats. 2015 , 18, 329-36	23
342	The promise of stem cells in the therapy of Alzheimer's disease. 2015 , 4, 8	13
341	The acetylcholine index: an electroencephalographic marker of cholinergic activity in the living human brain applied to Alzheimer's disease and other dementias. 2015 , 39, 132-42	21
340	Neurocognitive Aging and the Hippocampus across Species. 2015 , 38, 800-812	105
339	Aging Mechanisms. 2015 ,	3
338	Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. 2015 , 232, 1859-66	41
337	Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets. 2015 , 15, 53-71	17
336	A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid- β -Driven Inflammation in Down Syndrome. 2016 , 15, 434-47	20
335	Protection Efficacy of the Extract of <i>Ginkgo biloba</i> against the Learning and Memory Damage of Rats under Repeated High Sustained +Gz Exposure. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016 , 2016, 6320586	2.3 12
334	Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease. 2016 , 5, 333-342	19
333	Toxin-Induced Experimental Models of Learning and Memory Impairment. 2016 , 17,	51
332	Deep Phosphoproteomic Measurements Pinpointing Drug Induced Protective Mechanisms in Neuronal Cells. 2016 , 7, 635	4

331	An invertebrate-specific miRNA targeted the ancient cholinergic neuroendocrine system of oyster. 2016 , 6,	17
330	Subtle learning and memory impairment in an idiopathic rat model of Alzheimer's disease utilizing cholinergic depletions and β -amyloid. 2016 , 1646, 12-24	11
329	Generation of Human Embryonic Stem Cell Line Expressing zsGreen in Cholinergic Neurons Using CRISPR/Cas9 System. 2016 , 41, 2065-74	6
328	An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. 2016 , 12, 1132-1148	62
327	Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495. 2016 , 111, 169-179	23
326	Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. 2016 , 91, 1199-1218	304
325	Amelioration of scopolamine-induced amnesia by phosphatidylserine and curcumin in the day-old chick. 2016 , 27, 536-41	5
324	Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease. 2016 , 37, 1403-35	47
323	First in human study with a prodrug of galantamine: Improved benefit-risk ratio?. 2016 , 2, 13-22	10
322	Practical Pharmacology for Alzheimer's Disease. 2016 ,	1
321	Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease. 2016 , 107, 63-81	145
320	Two decades of new drug discovery and development for Alzheimer's disease. 2017 , 7, 6046-6058	45
319	White matter lesions and the cholinergic deficit in aging and mild cognitive impairment. 2017 , 53, 27-35	23
318	An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1676-1687	3.8 10
317	David A. Drachman, MD (1932-2016). 2017 , 88, 928-929	
316	Choline induces opposite changes in pyramidal neuron excitability and synaptic transmission through a nicotinic receptor-independent process in hippocampal slices. 2017 , 469, 779-795	8
315	Upregulation of neurotrophins by S 47445, a novel positive allosteric modulator of AMPA receptors in aged rats. 2017 , 121, 59-69	13
314	Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome. 2017 , 817, 7-19	10

313	WITHDRAWN: Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research. 2017 ,	13
312	A structural MRI study of cholinergic pathways and cognition in multiple sclerosis. 2017 , 8, 11-16	3
311	A novel DSC approach for evaluating protectant drugs efficacy against dementia. 2017 , 1863, 2934-2941	10
310	Novel dehydroabietylamine derivatives as potent inhibitors of acetylcholinesterase. 2017 , 74, 145-157	18
309	Main Plant Extracts' Active Properties Effective on Scopolamine-Induced Memory Loss. 2017 , 32, 418-428	8
308	The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test. 2017 , 79, 155-161	16
307	A second wind for the cholinergic system in Alzheimer's therapy. 2017 , 28, 112-123	37
306	Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer's disease treatment. 2017 , 1863, 607-619	30
305	Clinical Research in Neurology. 2017 , 555-571	
304	The Cholinergic System Modulates Memory and Hippocampal Plasticity Its Interactions with Non-Neuronal Cells. 2017 , 8, 1489	97
303	Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. 2017 , 108, 307-323	46
302	Recent advances in cholinergic imaging and cognitive decline-Revisiting the cholinergic hypothesis of dementia. 2018 , 7, 1-11	47
301	Ameliorating effect of <i>Alpinia oxyphylla</i> - <i>Schisandra chinensis</i> herb pair on cognitive impairment in a mouse model of Alzheimer's disease. 2018 , 97, 128-135	18
300	Effects of early-life malnutrition on neurodevelopment and neuropsychiatric disorders and the potential mechanisms. 2018 , 83, 64-75	40
299	The cholinergic system in the basal forebrain of the Atlantic white-sided dolphin (<i>Lagenorhynchus acutus</i>). 2018 , 526, 1910-1926	1
298	<i>Willughbeia cochinchinensis</i> prevents scopolamine-induced deficits in memory, spatial learning, and object recognition in rodents. 2018 , 214, 99-105	6
297	Treatment of obstructive sleep apnoea-hypopnea syndrome by mandible advanced device reduced neuron apoptosis in frontal cortex of rabbits. 2018 , 40, 273-280	2
296	Post-Injury Administration of Galantamine Reduces Traumatic Brain Injury Pathology and Improves Outcome. 2018 , 35, 362-374	20

295	Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression. 2018 , 84, 289-298		26
294	The Limbic System, Temporal Lobe, and Prefrontal Cortex. 2018 , 477-529		1
293	Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. <i>Brain Sciences</i> , 2018 , 8,	3-4	72
292	Molecular Imaging of the Cholinergic System in Parkinson's Disease. 2018 , 141, 211-250		27
291	Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research. 2019 , 6, 2-15		61
290	Impaired object-location learning and recognition memory but enhanced sustained attention in M2 muscarinic receptor-deficient mice. 2018 , 235, 3495-3508		7
289	Development of an Efficient Synthesis of an Agonist of Acetylcholine Nicotinic Receptor. 2018 , 22, 1419-1425		
288	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. 2018 , 141, 1917-1933		492
287	, a Traditional Korean Multiple Herbal Formulae, Improves Hippocampal Memory on Scopolamine Injection-Induced Amnesia Model of C57BL/6 Mice. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018 , 2018, 2821040	2-3	2
286	The Quest for an Alzheimer Therapy. 2018 , 9, 108		17
285	Novel 12-hydroxydehydroabietylamine derivatives act as potent and selective butyrylcholinesterase inhibitors. 2019 , 90, 103092		5
284	Acetylcholine. 2019 , 345-367		0
283	Prediction of AChE-ligand affinity using the umbrella sampling simulation. <i>Journal of Molecular Graphics and Modelling</i> , 2019 , 93, 107441	2-8	16
282	Redox active metals in neurodegenerative diseases. 2019 , 24, 1141-1157		31
281	Subjective Cognitive Decline and Biomarkers of Preclinical Alzheimer's Disease. 2019 , 6, 219-226		1
280	Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer's disease. 2019 , 19, 154-170		18
279	Chronic cerebral hypoperfusion-induced memory impairment and hippocampal long-term potentiation deficits are improved by cholinergic stimulation in rats. 2019 , 71, 443-448		17
278	The Brain NGF Metabolic Pathway in Health and in Alzheimer's Pathology. <i>Frontiers in Neuroscience</i> , 2019 , 13, 62	5-1	42

277	Ginsenosides Rg5 and Rk1 Enriched Cultured Wild Ginseng Root Extract Bioconversion of : Effect on Scopolamine-Induced Memory Dysfunction in Mice. 2019 , 11,		10
276	Neuroprotective effects of berberine in animal models of Alzheimer's disease: a systematic review of pre-clinical studies. 2019 , 19, 109		44
275	Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. <i>Frontiers in Neuroscience</i> , 2019 , 13, 446	5.1	68
274	Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology. 2019 , 92, e1580-e1588		58
273	Innovative Therapy for Alzheimer's Disease-With Focus on Biodelivery of NGF. <i>Frontiers in Neuroscience</i> , 2019 , 13, 38	5.1	67
272	Oral administration of lutein attenuates ethanol-induced memory deficit in rats by restoration of acetylcholinesterase activity. 2019 , 204, 121-128		7
271	Episodic and Semantic Memory Disorders. 2019 , 619-639		
270	Muscarinic and Nicotinic Modulation of Memory but not Verbal Problem-solving. 2019 , 32, 278-283		
269	Molecular Docking and Recent Advances in the Design and Development of Cholinesterase Inhibitor Scaffolds: Coumarin Hybrids. 2019 , 4, 14140-14156		4
268	Mechanisms of Aging-Related Cognitive Decline. 2019 , 226-244		
267	Impairments of attention in Alzheimer's disease. 2019 , 29, 41-48		9
266	New approaches for the treatment of Alzheimer's disease. 2019 , 29, 125-133		53
265	Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease. 2019 , 10, 852-862		54
264	The antioxidant 2,3-dichloro,5,8-dihydroxy,1,4-naphthoquinone inhibits acetyl-cholinesterase activity and amyloid β aggregation: A dual target therapeutic candidate compound for the treatment of Alzheimer's disease. 2020 , 67, 983-990		2
263	Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. 2020 , 30, 2083-2098		9
262	The effect of insomnia on development of Alzheimer's disease. 2020 , 17, 289		13
261	Synthesis and in vitro evaluation of vanillin derivatives as multi-target therapeutics for the treatment of Alzheimer's disease. 2020 , 30, 127505		7
260	Modulation of arousal and sleep/wake architecture by M PAM VU0453595 across young and aged rodents and nonhuman primates. 2020 , 45, 2219-2228		3

259	Merged Tacrine-Based, Multitarget-Directed Acetylcholinesterase Inhibitors 2015-Present: Synthesis and Biological Activity. 2020 , 21,	14
258	c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer's Diseases. 2020 , 21,	10
257	Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?. 2020 , 21,	23
256	Neuroprotective effect of red quinoa seeds extract on scopolamine-induced declarative memory deficits in mice: The role of acetylcholinesterase and oxidative stress. 2020 , 69, 103958	8
255	Cognitive Aging: The Role of Neurotransmitter Systems. 2020 , 82-100	2
254	Effect of Colloidal Aqueous Solution of Fullerene (C60) in the Presence of a P-Glycoprotein Inhibitor (Verapamil) on Spatial Memory and Hippocampal Expression of Sirtuin6, SELADIN1, and AQP1 Genes in a Rat Model of Alzheimer's Disease. 2020 , 11, 2549-2565	8
253	Amyloid- β tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues. 2020 , 31, 391-413	26
252	Cholinergic white matter pathways make a stronger contribution to attention and memory in normal aging than cerebrovascular health and nucleus basalis of Meynert. 2020 , 211, 116607	22
251	Progress in Target Drug Molecules for Alzheimer's Disease. 2020 , 20, 4-36	17
250	Dynamics analysis of the hippocampal neuronal model subjected to cholinergic action related with Alzheimer's disease. 2020 , 14, 483-500	6
249	Effects of Prolonged Seizures on Basal Forebrain Cholinergic Neurons: Evidence and Potential Clinical Relevance. 2020 , 38, 249-265	1
248	Walnut Oil Prevents Scopolamine-Induced Memory Dysfunction in a Mouse Model. 2020 , 25,	9
247	Ginseng gintonin, aging societies, and geriatric brain diseases. 2021 , 10, 100450	13
246	Modulation of NMDA Receptors by G-protein-coupled receptors: Role in Synaptic Transmission, Plasticity and Beyond. 2021 , 456, 27-42	11
245	Novel amyloid-beta pathology C. elegans model reveals distinct neurons as seeds of pathogenicity. 2021 , 198, 101907	3
244	Estimating the ligand-binding affinity via Edependent umbrella sampling simulations. 2021 , 42, 117-123	7
243	Altered heart rate variability during sleep in mild cognitive impairment. 2021 , 44,	3
242	A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology. 2021 , 148, 105150	6

241	Linking aging, anticholinergic drugs use, and cognitive impairment. 2021 , 453-461	
240	The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery : NGF Pathway Biomarkers and Drug Targets. 2021 , 1331, 31-48	2
239	Drug-Induced Disorders of Memory and Dementia. 2021 , 209-231	0
238	Anti-dementia Medication. 2021 , 73-104	
237	Tacrine - Benzothiazoles: Novel class of potential multitarget anti-Alzheimer's drugs dealing with cholinergic, amyloid and mitochondrial systems. 2021 , 107, 104596	4
236	Neurodegeneration: Diagnosis, Prevention, and Therapy.	1
235	Beneficial effects of angiotensin converting enzyme inhibition on scopolamine-induced learning and memory impairment in rats, the roles of brain-derived neurotrophic factor, nitric oxide and neuroinflammation. 2021 , 43, 505-515	1
234	Specific Phospholipid Modulation by Muscarinic Signaling in a Rat Lesion Model of Alzheimer's Disease. 2021 , 12, 2167-2181	2
233	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. 2021 , 82, 71-105	7
232	Neuroprotective Effect and Antioxidant Potency of Fermented Cultured Wild Ginseng Root Extracts of C.A. Meyer in Mice. 2021 , 26,	2
231	Neuronal Hyperexcitability in APPSWE/PS1dE9 Mouse Models of Alzheimer's Disease. 2021 , 81, 855-869	0
230	Consumption of Ashtanga Ghrita (clarified cow butter added with herb extracts) improves cognitive dysfunction induced by scopolamine in rats via regulation of acetylcholinesterase activity and oxidative stress. 2021 , 36, 337-350	0
229	Dysregulation of Astrocyte-Neuronal Communication in Alzheimer's Disease. 2021 , 22,	3
228	Increasing dietary choline attenuates spatial memory deficits resulting from exposure to the chemotherapeutic agents cyclophosphamide and doxorubicin. 2021 , 35, 1300-1309	0
227	Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors. 2021 , 19, 1323-1344	5
226	Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance. 2021 , 158, 1394-1411	2
225	Multifaceted Alzheimer's Disease: Building a Roadmap for Advancement of Novel Therapies. 2021 , 46, 2832-2851	3
224	CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 704583	5-3 2

223	Intrahippocampal blockade of nicotinic or muscarinic receptors fails to impair nonnavigational spatial memory in macaques. 2021 , 135, 581-590		0
222	Porphyromonas gingivalis Outer Membrane Vesicles as the Major Driver of and Explanation for Neuropathogenesis, the Cholinergic Hypothesis, Iron Dyshomeostasis, and Salivary Lactoferrin in Alzheimer's Disease. 2021 , 82, 1417-1450		7
221	Controlling the past, owning the present, and future: cholinergic modulation decreases semantic perseverations in a person with post-stroke aphasia. 1-19		0
220	Cholinergic Deep Brain Stimulation for Memory and Cognitive Disorders. 2021 , 83, 491-503		1
219	Effects of New Galantamine Derivatives in a Scopolamine Model of Dementia in Mice. 2021 , 84, 671-690		2
218	Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2021 , 15, 665820	5.1	3
217	Acorus calamus. 2021 , 337-349		1
216	Gene and cell therapy for the nucleus basalis of Meynert with NGF in Alzheimer's disease. 2021 , 179, 219-229		
215	Enlargement of early endosomes and traffic jam in basal forebrain cholinergic neurons in Alzheimer's disease. 2021 , 179, 207-218		1
214	Single neuron firing cascades underlie global spontaneous brain events.		0
213	Rita Levi-Montalcini, NGF Metabolism in Health and in the Alzheimer's Pathology. 2021 , 1331, 119-144		1
212	Drug effects on learning and memory1. 2002 , 595-643		3
211	Biochemical Changes in Alzheimer's Disease in Relation to Histopathology, Clinical Findings and Pathogenesis. 1981 , 253-268		1
210	Cholinesterase Inhibitors Do More than Inhibit Cholinesterase. 1997 , 187-204		8
209	Cholinergic drug studies in dementia and depression. 1990 , 282, 65-76		21
208	Central Cholinergic Pathways Neuroanatomy and Some Behavioral Implications. 1988 , 237-260		28
207	New Pharmacological Perspectives on Nootropic Drugs. 1988 , 437-469		5
206	Basal Forebrain Cholinergic Neurons and Alzheimer's Disease. 1988 , 69-106		19

205	Behavioral Models of Aging in Nonhuman Primates. 1988 , 325-392	6
204	Alzheimer's Disease. 1990 , 361-391	1
203	Cholinergic Systems in the Brain and Spinal Cord: Anatomic Organization and Overview of Functions. 1986 , 5-16	1
202	Pharmacological Activity of Novel Anticholinesterase Agents of Potential Use in the Treatment of Alzheimer's Disease. 1986 , 539-549	12
201	Recovery of Function in Senile Dementia of the Alzheimer Type. 1984 , 207-217	2
200	Cholinergic Excitability and Memory: Animal Studies and their Clinical Implications. 1979 , 175-204	5
199	Brain Acetylcholine and Disorders of Memory. 1979 , 205-213	5
198	Carbohydrates and Acetylcholine Synthesis: Implications for Cognitive Disorders. 1979 , 215-236	14
197	Optimizing Drugs for Brain Action. 2001 , 281-309	1
196	Different Influence of Inhibitors on Acetylcholinesterase Molecular forms G1 and G4 Isolated from Alzheimer's Disease and Control Brains. 1992 , 243-249	6
195	Neural transplantation and recovery of function: animal studies. 1992 , 325, 35-65	4
194	Differential Effect of Aging on Hippocampal Pyramidal Cell Responses to Muscarine and Nicotine. 1992 , 57-73	2
193	Acetylcholinesterase in the Cortex. 1987 , 187-236	4
192	Neuropsychological Investigations of Dementia. 1994 , 327-354	1
191	The Role of Genotype in Behavioral Responses to Anesthetics. 1975 , 229-321	1
190	Neurotransmitter Systems in Hippocampus and Prelimbic Cortex, Dopamine-Acetylcholine Interactions in Hippocampus, and Memory in the Rat. 1992 , 159-182	1
189	The Basal Forebrain Cholinergic System: An Evolving Concept in the Neurobiology of the Forebrain. 1991 , 11-71	3
188	Historical Overview of Research on Cholinergic Systems and Behavior. 1985 , 1-35	1

187	Exploitable Aspects of Central Cholinergic Functions, Particularly with Respect to the EEG, Motor, Analgesic and Mental Functions. 1978 , 679-708	9
186	Cholinergic Systems and Disorders of Carbohydrate Catabolism. 1978 , 791-803	9
185	Cholinergic Pathways in CNS. 1978 , 315-355	32
184	Cholinergic Systems and Cholinergic Pathology. 1984 , 379-410	11
183	Cholinergic Dysfunction and Memory; Implications for the Development of Animal Models of Aging and Dementia. 1986 , 205-213	2
182	AF102B: A Novel M1 Agonist as a Rational Treatment Strategy in Alzheimer's Disease. 1989 , 11-16	1
181	Alterations in Muscarinic Cholinergic Receptors and the Second Messenger System in the Cerebral Cortex in Alzheimer-Type Dementia. 1990 , 553-558	1
180	Developmental Reorganization of the Human Association Cortex during Perinatal and Postnatal Life. 1992 , 3-17	4
179	Evolution of Cholinergic Cortical Innervation after nbM-Lesioning (An Experimental Alzheimer Model). 1992 , 173-198	2
178	Cholinomimetic Agents and Human Memory: Preliminary Observations in Alzheimer's Disease. 1981 , 929-936	2
177	Loss of choline acetyltransferase activity in normal aging and in senile dementia. 1978 , 113, 251-6	23
176	Afferents to basal forebrain cholinergic projection neurons: an update. 1991 , 295, 43-100	93
175	Effects of Lecithin on Memory and Learning. 1987 , 147-153	1
174	Polyunsaturated Fats and Learning. 1997 , 215-244	1
173	Designing Drugs for Optimal Nervous System Activity. 1995 , 251-264	9
172	Monoaminergic Innervation of Cingulate Cortex. 1993 , 285-310	15
171	Functional Cholinergic Receptor Sensitivity: The Role of Drug Probes. 1991 , 170-182	1
170	Physostigmine in Alzheimer's Disease. 1991 , 209-215	3

169	New Nicotinic Agonists and Cerebral Blood Flow. 1991 , 386-394	1
168	The Aged Dog as a Natural Model of Alzheimer's Disease Progression. 2017 , 69-92	2
167	Drug Discovery and Evaluation: Methods in Clinical Pharmacology. 2011 , 423-455	2
166	Muscarinic receptor pharmacology and circuitry for the modulation of cognition. 2012 , 121-66	75
165	Clinical Aspects of Nicotinic Agents: Therapeutic Applications in Central Nervous System Disorders. 2000 , 779-812	9
164	Neurotransmitters in Normal Aging. 1982 , 263-282	7
163	Animal Models of Geriatric Cognitive Dysfunction: Evidence for an Important Cholinergic Involvement. 1985 , 269-282	5
162	Beta-carbolines as tools in memory research: animal data and speculations. 1988 , 6, 230-45	16
161	Influence of Physostigmine on Cognitive Processing of the Brain. 1989 , 429-435	2
160	Neuere pharmakologische Modelle und Forschungsergebnisse in der Therapie der degenerativ und/oder vaskulär bedingten hirnrorganischen Psychosyn-drome bzw. Demenzen im mittleren und höheren Lebensalter. 1986 , 77-113	5
159	Drug effects on learning and memory. 1997 , 317-349	1
158	Acetylcholinmangelhypothese der Demenz und ihre klinisch-therapeutische Überprüfung. 1996 , 38-48	2
157	The need for early markers in Alzheimer's disease. 1990 , 137-146	1
156	Knowledge of Signal Transduction Provides an Approach to Attacking Memory Decline. 2015 , 257-274	1
155	Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. 1988 , 472, 371-89	52
154	THE SUBSTANTIA NIGRA AND NEOSTRIATUM: SUBSTRATES FOR MEMORY CONSOLIDATION. 1978 , 305-331	6
153	Hippocampal Transplants in Oculo: A Model for Establishment of Isolated Circuits. 1991 , 327-345	8
152	Biochemical, Morphological and Functional Changes in the Developing Brain. 1977 , 1-13	6

151	APPLIED ASPECTS OF MEMORY RESEARCH: AGING. 1986 , 203-233	2
150	Central Nervous System Disorders in Aging. 1990 , 306-329	2
149	Antidepressant Drugs, Cognitive Function and Human Performance. 1992 , 319-336	2
148	Central neurotoxicity and behavioural effects of anticholinesterases. 1992 , 75-83	12
147	Toward a Neurochemistry of Naming and Anomia. 2000 , 157-165	2
146	MULTITRANSMITTER MECHANISMS UNDERLYING SELECTED FUNCTION, PARTICULARLY AGGRESSION, LEARNING AND SEXUAL BEHAVIOR. 1978 , 581-608	1
145	Dementia in the Aged. 1982 , 5, 67-86	11
144	The nucleus basalis of Meynert. 1986 , 13, 8-14	41
143	Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans. 1995 , 15, 58-62	11
142	A New Visual Scale to Assess White Matter Hyperintensities Within Cholinergic Pathways. 2005 , 36, 2064-2065	2
141	Drug treatments of dementia. 1989 , 155, 595-611	23
140	Muscarinic Receptor Antagonists in Rats. 2006 , 5-20	2
139	Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers. 2011 , 6, e24126	37
138	Decreased response to acetylcholine during aging of aplysia neuron R15. 2013 , 8, e84793	14
137	Acetylcholinesterase and Butyrylcholinesterase Important Enzymes of Human Body. 2004 , 47, 215-228	52
136	Biophysical Basis of Alpha Rhythm Disruption in Alzheimer's Disease. 2020 , 7,	1
135	A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease. 2019 , 26, 5625-5648	15
134	Mechanisms of Melatonin in Alleviating Alzheimer's Disease. 2017 , 15, 1010-1031	89

133	Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer's Disease. 2020 , 19, 85-93	20
132	Pharmacological models in Alzheimer's disease research. 2000 , 2, 247-55	22
131	Age and Heat Stress Related Changes in Monoamine Contents and Cholinesterase Activity in Some Central Nervous System Regions of Albino Rat Newborns. 2007 , 3, 65-76	2
130	Pharmacologic Approach to the Treatment of Senile Dementia. 1983 , 13, 14-30	8
129	Alzheimer's Disease or "Alzheimerism"?. 1984 , 14, 130-132	1
128	Houttuynia cordata Improves Cognitive Deficits in Cholinergic Dysfunction Alzheimer's Disease-Like Models. 2014 , 22, 176-83	15
127	Role of Cholinesterase Inhibitors in Managing Behavioral Problems in Alzheimer's Disease. 2004 , 6, 126-131	5
126	New Pyrimidine and Pyridine Derivatives as Multitarget Cholinesterase Inhibitors: Design, Synthesis, and and Evaluation. 2021 , 12, 4090-4112	2
125	Clues and Chemical Leads. 2000 , 167-179	
124	Peter Davies. 2000 , 199-210	
123	The Cholinergic Hypothesis a Generation Later. 2000 , 3-45	1
122	Literatur. 2000 , 192-251	
121	References. 2000 , 257-302	
120	Cholinergic Lesions as a Model of Alzheimer's Disease. 2000 , 65-80	1
119	Estrogens and Alzheimer's Disease. 2001 , 469-473	
118	Cholinergic Plasticity and the Meaning of Death. 2003 , 27-74	
117	The cholinergic hypothesis [past and present. 2004 , 1-10	1
116	Muscarinic Receptor Antagonists in Rats. 2006 , 23-38	

- 115 Cholinergic Neurodegeneration in Alzheimer's Disease: Basis for Nerve Growth Factor Therapy. **2007**, 64-104 2
- 114 Anti-Aging Strategies. **2008**, 305-317
- 113 Development of central neurotransmitter systems. **1981**, 86, 251-70 9
- 112 Neurologic and Cognitive Changes in the Elderly. **2011**, 321-338
- 111 Limbic System and the Temporal Lobe. **2011**, 275-304
- 110 Episodic and Semantic Memory Disorders. **2013**, 401-419
- 109 Die neurologischen Aspekte des Lernens: eine neuropharmakologische Untersuchung des Kurzzeitgedächtnisses. **1977**, 63-71
- 108 Central Cholinergic Dysfunctions in Man: Clinical Manifestations and Approaches to Diagnosis and Treatment. **1978**, 733-745
- 107 Mental disorders. **1979**, 35-64
- 106 Electrophysiological Effects of Choline Chloride in Elderly Subjects. **1979**, 361-370
- 105 The Treatment of Memory Deficits in the Aged with Choline Chloride. **1979**, 253-262
- 104 Cognitive Effects of Physostigmine and Choline Chloride in Normal Subjects. **1979**, 237-251
- 103 Cerebral activating drugs. **1980**, 295-331 1
- 102 Rapport der Diskussion. **1985**, 260-267
- 101 The Cholinergic Basis of Memory – A Reappraisal. **1985**, 63-68
- 100 Neurotransmitterveränderungen im alternden Gehirn. **1985**, 69-113 1
- 99 Repräsentativität von Probanden- und Patientenstudien. **1985**, 247-250 1
- 98 Biochemistry of Senile Dementia. **1985**, 617-650

- 97 Cognitive Analysis of Neuropharmacological Treatments. **1985**, 83-90
- 96 Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease. **1986**, 133-151 1
- 95 Neurotransmitter Alterations in the Aging Brain. **1986**, 61-101
- 94 Human and Animal Studies With Cholinergic Agents: How Clinically Exploitable is the Cholinergic Deficiency in Alzheimer's Disease. **1986**, 531-537
- 93 Neurochemical and Behavioral Alterations in Aging and in Animal Models of Alzheimer's Disease. **1986**, 393-405 1
- 92 Two Drug Binding Sites on Muscarinic Receptors. **1986**, 103-121 1
- 91 Rapport der Diskussion. **1987**, 144-156
- 90 Neurotransmitters in the Ageing Brain and Dementia. **1987**, 99-112
- 89 Benzodiazepine receptor ligands: tools for memory research in clinical pharmacology. **1988**, 6, 261-74 2
- 88 Central Cholinergic Neuropathologies. **1988**, 725-743 1
- 87 Strukturelle und funktionelle Altersveränderungen des Gehirns. **1988**, 232-240
- 86 Age-Related Changes in Rat Hippocampal Noradrenergic Transmission: Insights from In Oculo Transplants. **1989**, 130-140
- 85 Affective Disorders in Elderly and Dementing Patients. **1989**, 90-125 0
- 84 Neurotransmitters in the brain. **1989**, 39, 1025-9; discussion 1029-30
- 83 Neurobiologie dementieller Syndrome [Neurochemie und Neuropharmakologie der Nootropika. **1990**, 63-71
- 82 (+)-Cis-Methyl-Spiro(1,3-Oxathiolane-5,3?)Quinuclidine (AF102B): A New M1 Agonist as a Rational Treatment Strategy in Alzheimer's Disease - An Overview. **1990**, 309-319 2
- 81 Central Nervous System Disorders in Aging. **1990**, 306-329
- 80 Some Effects of CNS Cholinergic Neurons on Memory and ACh Release. **1990**, 753-756

- 79 Some effects of CNS cholinergic neurons on memory. **1990**, 30, 1-11 6
- 78 Alzheimer Disease and Other Dementias. **1990**, 353-388 1
- 77 A Case of Alzheimerism Induced by Trihexyphenidyl. **1990**, 163-164
- 76 Drug treatment of dementia. **1990**, 545-554 1
- 75 Actions of Acetylcholine on Cortical Neurons: Pieces in the Puzzle About Mechanisms Underlying Learning. **1991**, 167-187 0
- 74 The Effects of Nerve Growth Factor on the Central Nervous System of the Adult Primate. **1991**, 427-444
- 73 Adult Development and Aging. **1992**, 81-119 2
- 72 The psychopharmacology of human memory disorders. **1992**, 189-215 1
- 71 Serotonin Influences on Cholinergic Function: Possible Interactions in Learning and Memory. **1992**, 207-227
- 70 The Effects of Acetylcholine and Aging on Electrical Excitability of the Central Nervous System. **1993**, 5-23
- 69 Bibliography. **1993**, 247-301
- 68 Alzheimer's Disease. **1994**, 261-270
- 67 Animal Models of Alzheimer's Disease. **1994**, 239-265 2
- 66 Treatment of Alzheimer's Disease. **1996**,
- 65 Current Research on Alzheimer's disease in a Historical Perspective. **1996**,
- 64 Anatomy and Physiology of the Aging Human Brain. **1997**, 32-43 1
- 63 The Rationale for Development of Cholinergic Therapies in ad. **1998**, 445-450
- 62 Alzheimer's Disease. **1999**, 77-101

61	Exkurs: Kognitive Störungen bei Morbus Parkinson. 1999 , 356-373		
60	Cholinergic Basal Forebrain Grafts in Rodent and Nonhuman Primate Models of Alzheimer's Disease. 1999 , 555-580		
59	Dementia and Other Neurocognitive Disorders. 2017 , 226-252		
58	ALZHEIMERIO LIGOS GYDYMŲ METODŲ PAIEŲA: KLINIKINIŲ TYRIMŲ KRYPTYS. 2018 , 22, 21-30		
57	Neurological Manifestations of Nutritional Deficiencies. 1983 , 191-210		
56	Precursor-directed Biosynthesis in <i>Tabernaemontana catharinensis</i> as a New Avenue for Alzheimer's Disease-modifying Agents. <i>Planta Medica</i> , 2021 , 87, 136-147	3.1	0
55	Deep Brain Stimulation for Alzheimer's Disease: Tackling Circuit Dysfunction. <i>Neuromodulation</i> , 2021 , 24, 171-186	3.1	9
54	Molecular Modelling Based Design and Synthesis of Donepezil Like Derivatives As Acetylcholinesterase Inhibitors. <i>SSRN Electronic Journal</i> ,	1	
53	Dementia and Other Neurocognitive Disorders. <i>Advances in Psychology, Mental Health, and Behavioral Studies</i> , 104-130	0.2	
52	Therapies for dementia?. <i>Medical Journal of Australia</i> , 1985 , 143, 102-4	4	1
51	Exploring the Role of Acetylcholine in Primate Cognition Using Me20.4 IgG-Saporin. 2005 , 101-142		
50	Drugs That Affect Competence. 2008 , 41-50		1
49	[Relations between specific neurochemical systems and memory: problems posed by dementia of the Alzheimer type]. <i>Journal of Psychiatry and Neuroscience</i> , 1995 , 20, 49-66	4.5	3
48	Development of pharmacological treatments for Alzheimer-type dementia. <i>Journal of the Royal Society of Medicine</i> , 1994 , 87 Suppl 23, 19-21	2.3	
47	Probing peripheral and central cholinergic system responses. <i>Journal of Psychiatry and Neuroscience</i> , 2000 , 25, 325-36	4.5	4
46	Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. <i>Clinical Interventions in Aging</i> , 2010 , 5, 1-6	4	15
45	m1 Acetylcholine Receptor Expression is Decreased in Hippocampal CA1 region of Aged Epileptic Animals. 2011 , 2, 301-7		5
44	Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults. <i>Missouri Medicine</i> , 2016 , 113, 207-14	0.8	14

43	A Debatable Top Ten Papers in Geriatric Medicine List. <i>Canadian Geriatrics Journal</i> , 2020 , 23, 228-234	2.8	
42	Single-neuron firing cascades underlie global spontaneous brain events. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	1
41	Radioligands for Imaging of the CNS Acetylcholinergic System. 2022 , 179-189		
40	Intrahippocampal Adeno-Associated Virus-Mediated Overexpression of Nerve Growth Factor Reverses 192IgG-Saporin-Induced Impairments of Hippocampal Plasticity and Behavior. <i>Frontiers in Neuroscience</i> , 2021 , 15, 745050	5.1	1
39	A Debatable Top Ten Papers in Geriatric Medicine List. <i>Canadian Geriatrics Journal</i> , 2020 , 23, 263-269	2.8	0
38	Genome Editing Technology for the Study and Correction of Neurodegenerative Diseases. <i>Neurochemical Journal</i> , 2021 , 15, 339-352	0.5	
37	The Effect of Guilingji Capsules on Vascular Mild Cognitive Impairment: A Randomized, Double-Blind, Controlled Trial.. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022 , 2022, 4778163	2.3	0
36	Synthesis, characterizations of aryl-substituted dithiodibenzothioate derivatives, and investigating their anti-Alzheimer's properties.. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022 , 1-18	3.6	
35	Muscarinic Acetylcholine Receptor Localization on Distinct Excitatory and Inhibitory Neurons Within the ACC and LPFC of the Rhesus Monkey.. <i>Frontiers in Neural Circuits</i> , 2021 , 15, 795325	3.5	0
34	Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's Disease.. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	0
33	Poststroke aphasia treatment: A review of pharmacologic therapies and noninvasive brain stimulation techniques. <i>The Journal of the International Society of Physical and Rehabilitation Medicine</i> , 2022 ,	0.6	
32	Hope or hype? Aducanumab as a magic bullet for Alzheimer's disease. <i>BIO Integration</i> , 2022 ,	4.1	1
31	Recent Advances in Understanding of Alzheimer's Disease Progression Through Mass Spectrometry-Based Metabolomics. <i>Phenomix</i> , 2022 , 2, 1-17		1
30	A review on the neuroprotective effect of berberine against chemotherapy-induced cognitive impairment.. <i>Current Drug Targets</i> , 2022 ,	3	
29	A Network Pharmacology Based Research on the Mechanism of Donepezil in Treating Alzheimer's Disease.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 822480	5.3	
28	Targeting the M1 muscarinic acetylcholine receptor in Alzheimer's disease.. <i>Neuronal Signaling</i> , 2022 , 6, NS20210004	3.7	1
27	The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy.. <i>Cells</i> , 2021 , 11,	7.9	0
26	Attenuation of scopolamine-induced deficits in delayed-matching performance by a new muscarinic agonist. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 1997 , 25, 313-320		4

25	Searching for AChE inhibitors from natural compounds by using machine learning and atomistic simulations. <i>Journal of Molecular Graphics and Modelling</i> , 2022 , 115, 108230	2.8	0
24	Identifying Possible AChE Inhibitors from Drug-like Molecules via Machine Learning and Experimental Studies. <i>ACS Omega</i> , 2022 , 7, 20673-20682	3.9	4
23	Acetylcholine bidirectionally regulates learning and memory. <i>Journal of Neurorestoratology</i> , 2022 , 1000023	3.3	0
22	Three-Dimensional Spatial Analyses of Cholinergic Neuronal Distributions Across The Mouse Septum, Nucleus Basalis, Globus Pallidus, Nucleus Accumbens, and Caudate-Putamen. <i>Neuroinformatics</i> ,	3.2	
21	Amelioration of Scopolamine-Induced Cognitive Dysfunction in Experimental Mice Using the Medicinal Plant <i>Salvia moorcroftiana</i> . <i>Brain Sciences</i> , 2022 , 12, 894	3.4	2
20	Muscarinic and N-methyl-D-aspartate receptor blockade reveal differences in hippocampal local field potentials in mice with low cholinergic tone.		0
19	Long-term nucleus basalis cholinergic depletion induces attentional deficits and impacts cortical neurons and BDNF levels without affecting the NGF synthesis.		
18	Normalized Theta but Increased Gamma Activity after Acetylcholinesterase Inhibitor Treatment in Alzheimer's Disease: Preliminary qEEG Study. 155005942211207		0
17	Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. 1-16		1
16	Acupuncture and Alzheimer's Disease. 2022 , 635-665		0
15	Loss of Cholinergic Receptor Muscarinic 1 (CHRM1) Protein in the Hippocampus and Temporal Cortex of a Subset of Individuals with Alzheimer's Disease, Parkinson's Disease, or Frontotemporal Dementia: Implications for Patient Survival. 2022 , 1-21		0
14	Self-generated brain-wide spiking cascades govern replay dynamics in the hippocampus.		0
13	Therapeutic Implications of Glycogen Synthase Kinase-3 β in Alzheimer's disease: A Novel Therapeutic Target. 1-27		1
12	A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles. 2022 , 23,		1
11	A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. 2022 , 12, 2975		1
10	Altered microstructural pattern of the cortex and basal forebrain cholinergic system in wilson's disease: an automated fiber quantification tractography study.		0
9	Biological Activities of the Alkaloids of the Calabar Bean. 2023 , 169-224		0
8	The hyperexcitability of laterodorsal tegmentum cholinergic neurons accompanies adverse behavioral and cognitive outcomes of prenatal stress. 2023 , 13,		0

- 7 The pathomimetic oA β 25 β 5 model of Alzheimer's disease: Potential for screening of new therapeutic agents. **2023**, 245, 108398 ○
- 6 A novel transgenic mouse model expressing primate-specific nuclear choline acetyltransferase: insights into potential cholinergic vulnerability. **2023**, 13, ○
- 5 Basal forebrain cholinergic signalling: development, connectivity and roles in cognition. **2023**, 24, 233-251 ○
- 4 Lawsonia inermis flower aqueous extract expressed better anti-alpha-glucosidase and anti-acetylcholinesterase activity and their molecular dynamics. 1-14 ○
- 3 Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases. **2023**, 24, 6921 ○
- 2 Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimer's Disease. **2023**, 24, 7258 ○
- 1 New perspectives on the basal forebrain cholinergic system in Alzheimer's disease. **2023**, 105192 ○